Teleflex (TFX) 10-Q 4 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Apr. 02, 2017	May 01, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 2, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	TFX
Entity Registrant Name	TELEFLEX INCORPORATED
Entity Central Index Key	96,943
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		44,981,275

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Income Statement [Abstract]
Net revenues	$ 487,881	$ 424,893
Cost of goods sold	232,321	199,746
Gross profit	255,560	225,147
Selling, general and administrative expenses	163,969	136,348
Research and development expenses	17,827	12,353
Restructuring charges	12,945	9,968
Gain on sale of assets	0	(1,019)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	60,819	67,497
Interest expense	17,726	13,784
Interest income	(169)	(80)
Loss on extinguishment of debt	5,582	0
Income from continuing operations before taxes	37,680	53,793
(Benefit) taxes on income from continuing operations	(2,669)	2,613
Income from continuing operations	40,349	51,180
Operating loss from discontinued operations	(282)	(382)
Benefit on loss from discontinued operations	(103)	(70)
Loss from discontinued operations	(179)	(312)
Net income	40,170	50,868
Less: Income from continuing operations attributable to noncontrolling interest	0	179
Net income attributable to common shareholders	$ 40,170	$ 50,689
Basic:
Income from continuing operations (in dollars per share)	$ 0.90	$ 1.22
Loss from discontinued operations (in dollars per share)	(0.01)	0
Net income (in dollars per share)	0.89	1.22
Diluted:
Income from continuing operations (in dollars per share)	0.87	1.05
Loss from discontinued operations (in dollars per share)	(0.01)	(0.01)
Net income (in dollars per share)	0.86	1.04
Dividends per share (in dollars per share)	$ 0.34	$ 0.34
Weighted average common shares outstanding
Basic (in shares)	44,893	41,647
Diluted (in shares)	46,615	48,782
Amounts attributable to common shareholders:
Income from continuing operations, net of tax	$ 40,349	$ 51,001
Income (loss) from discontinued operations, net of tax	(179)	(312)
Net income attributable to common shareholders	$ 40,170	$ 50,689

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 40,170	$ 50,868
Other comprehensive income, net of tax:
Foreign currency translation, net of tax of $(7,089) and $(4,177)	46,982	20,455
Pension and other postretirement benefit plans adjustment, net of tax of $(532) and $(629)	890	1,238
Derivatives qualifying as hedges, net of tax of $(555) and $(379)	1,728	1,480
Other comprehensive income, net of tax:	49,600	23,173
Comprehensive income	89,770	74,041
Less: comprehensive income attributable to noncontrolling interest	0	158
Comprehensive income attributable to common shareholders	$ 89,770	$ 73,883

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Statement of Comprehensive Income [Abstract]
Foreign currency translation, tax	$ (7,089)	$ (4,117)
Pension and other postretirement benefits plans adjustment, tax	(532)	(629)
Derivatives qualifying as hedges, tax	$ (555)	$ (379)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Apr. 02, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 689,129	$ 543,789
Accounts receivable, net	282,872	271,993
Inventories, net	355,289	316,171
Prepaid expenses and other current assets	47,238	40,382
Prepaid taxes	20,599	8,179
Assets held for sale	0	2,879
Total current assets	1,395,127	1,183,393
Property, plant and equipment, net	355,234	302,899
Goodwill	1,815,498	1,276,720
Intangible assets, net	1,620,454	1,091,663
Deferred tax assets	1,963	1,712
Other assets	44,160	34,826
Total assets	5,232,436	3,891,213
Current liabilities
Current borrowings	131,095	183,071
Accounts payable	82,018	69,400
Accrued expenses	82,390	65,149
Current portion of contingent consideration	669	587
Payroll and benefit-related liabilities	65,927	82,679
Accrued interest	12,686	10,450
Income taxes payable	8,043	7,908
Other current liabilities	9,530	8,402
Total current liabilities	392,358	427,646
Long-term borrowings	1,957,797	850,252
Deferred tax liabilities	460,654	271,377
Pension and postretirement benefit liabilities	130,226	133,062
Noncurrent liability for uncertain tax positions	17,939	17,520
Other liabilities	54,558	52,015
Total liabilities	3,013,532	1,751,872
Commitments and contingencies
Convertible notes - redeemable equity component	0	1,824
Mezzanine equity	0	1,824
Total shareholders' equity	2,218,904	2,137,517
Total liabilities and shareholders' equity	$ 5,232,436	$ 3,891,213

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Cash flows from operating activities of continuing operations:
Net income	$ 40,170	$ 50,868
Adjustments to reconcile net income to net cash provided by operating activities:
Loss (income) from discontinued operations	179	312
Depreciation expense	14,180	12,602
Amortization expense of intangible assets	18,785	15,357
Amortization expense of deferred financing costs and debt discount	1,406	4,377
Loss on extinguishment of debt	5,582	0
Gain on sale of assets	0	(1,019)
Fair value step up of acquired inventory sold	7,832	0
Changes in contingent consideration	179	377
Stock-based compensation	4,240	3,437
Deferred income taxes, net	(3,081)	756
Other	(2,703)	(3,114)
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	18,691	(10,568)
Inventories	(5,322)	(5,104)
Prepaid expenses and other current assets	(1,224)	(3,749)
Accounts payable and accrued expenses	2,696	4,502
Income taxes receivable and payable, net	(10,670)	(2,202)
Net cash provided by operating activities from continuing operations	90,940	66,832
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(12,894)	(7,822)
Proceeds from sale of assets	6,332	1,251
Payments for businesses and intangibles acquired, net of cash acquired	(975,524)	0
Net cash used in investing activities from continuing operations	(982,086)	(6,571)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	1,194,500	0
Reduction in borrowings	(138,251)	(9)
Debt extinguishment, issuance and amendment fees	(19,114)	0
Net proceeds from share based compensation plans and the related tax impacts	(505)	3,180
Payments for contingent consideration	(79)	(61)
Dividends paid	(15,287)	(14,179)
Net cash provided by (used in) financing activities from continuing operations	1,021,264	(11,069)
Cash flows from discontinued operations:
Net cash used in operating activities	(266)	(126)
Net cash used in discontinued operations	(266)	(126)
Effect of exchange rate changes on cash and cash equivalents	15,488	5,126
Net increase in cash and cash equivalents	145,340	54,192
Cash and cash equivalents at the beginning of the period	543,789	338,366
Cash and cash equivalents at the end of the period	689,129	392,558
Non cash financing activities of continuing operations:
Settlement and exchange of convertible notes with common or treasury stock	958	5
Acquisition of treasury stock associated with settlement and exchange of convertible note hedge and warrant agreements	$ 19,311	$ 11

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Beginning Balance at Dec. 31, 2015					$ (371,124)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 50,868
Other comprehensive (loss) income	23,173
Ending Balance at Mar. 27, 2016					(347,930)
Beginning Balance (in shares) at Dec. 31, 2016		45,814				1,741
Beginning Balance at Dec. 31, 2016	2,137,517	$ 45,814	$ 506,800	$ 2,194,593	(438,717)	$ (170,973)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	40,170			40,170
Cash dividends ($0.34 per share)	(15,287)			(15,287)
Other comprehensive (loss) income	49,600				49,600
Settlements of convertible notes (in shares)		928				0
Settlements of convertible notes	4,848	$ 928	3,890			$ 30
Settlements of note hedges associated with convertible notes (in shares)						119
Settlements of note hedges associated with convertible notes and warrants	2		19,311			$ (19,309)
Shares issued under compensation plans (in shares)		53				41
Shares issued under compensation plans	1,966	$ 53	(156)			$ 2,069
Deferred compensation (in shares)						(2)
Deferred compensation	88					$ 88
Ending Balance (in shares) at Apr. 02, 2017		46,795				1,817
Ending Balance at Apr. 02, 2017	$ 2,218,904	$ 46,795	$ 529,845	$ 2,219,476	$ (389,117)	$ (188,095)

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Statement of Stockholders' Equity [Abstract]
Dividends per share (in dollars per share)	$ 0.34	$ 0.34

Basis of presentation

Basis of presentation	3 Months Ended
	Apr. 02, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Note 1 — Basis of presentation The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our,” “Teleflex” and the “Company”) are prepared on the same basis as its annual consolidated financial statements. In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and with Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year. In accordance with applicable accounting standards, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements, but, as permitted by Rule 10-01 of SEC Regulation S-X, does not include all disclosures required by GAAP for complete financial statements. Accordingly, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2016 .

New accounting standards

New accounting standards	3 Months Ended
	Apr. 02, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	Note 2 — New accounting standards In May 2014, the FASB, in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. The new guidance is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective for annual periods beginning after December 15, 2017 and interim periods within those years. Although the Company's evaluation of this guidance is ongoing, the Company's preliminary assessment indicates that the adoption of this guidance will not have a material impact on the Company’s results of operations, cash flows and financial position. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; the guidance provides certain practical expedients. The Company is currently evaluating this guidance to determine its impact on the Company’s results of operations, cash flows and financial position. In March 2016, the FASB issued new guidance designed to simplify several aspects of the accounting for share-based payment transactions, including, among other things, guidance related to accounting for income taxes, modification of the criteria for classification of awards as either equity awards or liability awards where an employer withholds shares from an employee's share-based award for tax withholding purposes, and classification on the statement of cash flows of cash payments to a tax authority by an employer that withholds shares from an employee's award for tax withholding purposes. The Company adopted this standard as of January 1, 2017. The Company has applied the new guidance requiring recognition of excess tax deficiencies and tax benefits in the income statement, rather than in additional paid-in-capital, as previously required. The adoption of the new standard increased net income and cash flows from operating activities by $3.4 million ( $0.07 diluted earnings per share) for the three months ended April 2, 2017. The Company will continue to estimate forfeitures of share-based awards at the time of grant, rather than recognize actual forfeitures as they occur, as permitted under the new guidance. In August 2016, the FASB issued new guidance with regard to eight specific issues pertaining to the classification of certain cash receipts and cash payments within the statement of cash flows. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. The new guidance should generally be adopted using a retrospective transition method for each period presented. Although the Company's evaluation of this guidance is ongoing, the Company's preliminary assessment indicates that the adoption of this guidance will not have a material impact on the Company's cash flows. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The guidance is effective for annual periods beginning after December 15, 2017, and early adoption is permitted as of the beginning of an annual reporting period. The guidance should be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the annual period of adoption. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In January 2017, the FASB issued new guidance to clarify the definition of a “business,” with the objective of assisting entities in evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or as an acquisition of a business. The definition of a business affects many areas of accounting, including acquisitions, disposals, goodwill and consolidation. The guidance generally defines a business as an integrated set of activities and assets (collectively referred to as a “set”) that is capable of being conducted and managed for the purpose of providing a return to investors or other owners, members, or participants. The guidance further provides that, to be considered a business, a set must meet specified requirements. However, the guidance also states that, if substantially all of the fair value of gross assets acquired (subject to specified exceptions) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not considered a business and no further analysis is required. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early application is permitted under specified circumstances. In January 2017, the FASB issued guidance to simplify the quantitative test for goodwill impairment. Under current guidance, if a reporting unit’s carrying value exceeds its fair value, the entity must determine the implied value of goodwill. This determination is made by deducting the fair value of a reporting unit’s identifiable assets and liabilities from the fair value of the reporting unit as a whole as if the reporting unit had just been acquired. Under the new guidance, a determination of the implied value of goodwill will no longer be required; a goodwill impairment will be equal to the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The revised guidance is effective for fiscal years, and any interim goodwill impairment tests within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In March 2017, the FASB issued new guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The new guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017 and generally is required to be applied retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated results of operations. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions

Acquisitions	3 Months Ended
	Apr. 02, 2017
Business Combinations [Abstract]
Acquisitions	Note 3 — Acquisitions On February 17, 2017, the Company completed the acquisition of Vascular Solutions, Inc. (“Vascular Solutions”) pursuant to the terms of an Agreement and Plan of Merger, dated as of December 1, 2016 (the "Merger Agreement"). Vascular Solutions is a medical device company that develops and markets products for use in minimally invasive coronary and peripheral vascular procedures. At the effective time of the Merger (the “Effective Time”), each share of common stock of Vascular Solutions (the “Shares”), other than Shares held by Vascular Solutions, Teleflex, or their respective subsidiaries, and Shares then held by a holder who has properly asserted dissenters’ rights under applicable law, was converted into the right to receive $56.00 per Share in cash, without interest and subject to applicable withholding tax (the “Merger Consideration”). In addition, each outstanding option or similar right to purchase Shares (other than pursuant to the employee stock purchase program of Vascular Solutions) issued under the Vascular Solutions’ Stock Option and Stock Award Plan (the "Company Options") was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the exercise price of such Company Option, subject to applicable withholding tax. The aggregate consideration transferred was approximately $975.5 million , net of cash acquired. Transaction expenses associated with the Vascular Solutions acquisition, which are included in selling, general and administrative expenses in the condensed consolidated statement of income were $8.9 million for the three months ended April 2, 2017 . For the period from February 18, 2017 through April 2, 2017 , the Company recorded post acquisition revenue and operating loss of $21.6 million and $14.8 million , respectively, related to Vascular Solutions. Financial information of Vascular Solutions is presented within the "All Other" category in the Company's presentation of segment information. The transaction was financed utilizing borrowings under the Amended and Restated Credit Agreement, dated January 20, 2017 (the "Credit Agreement"), which is described in Note 7. The following table presents the preliminary fair value determination of the assets acquired and liabilities assumed as of February 17, 2017 with respect to the Vascular Solutions acquisition, which was accounted for as a business combination: (Dollars in thousands) Assets Current assets $ 64,232 Property, plant and equipment 46,886 Intangible assets 539,250 Goodwill 521,396 Other assets 728 Total assets acquired 1,172,492 Less: Current liabilities 13,470 Deferred tax liabilities 183,498 Liabilities assumed 196,968 Net assets acquired $ 975,524 The Company is continuing to evaluate the initial purchase price allocation, and further adjustments may be necessary as a result of the Company's assessment of additional information related to the fair values of the assets acquired and liabilities assumed, primarily deferred tax liabilities, certain intangible assets and goodwill. The goodwill resulting from the acquisition primarily reflects synergies currently expected to be realized from the integration of the acquired business. The following table sets forth the components of identifiable intangible assets acquired and the ranges of the useful lives as of the date of acquisition: Fair value Useful life range (Dollars in thousands) (Years) Intellectual property 248,200 10- 20 In-process research and development ("IPR&D") 15,600 Indefinite Trade names 16,650 20 Customer lists 258,800 25 Pro forma combined financial information The following unaudited pro forma combined financial information for the three months ended April 2, 2017 and March 27, 2016, respectively, gives effect to the Vascular Solutions acquisition as if it was completed at the beginning of each of the respective periods. Three Months Ended April 2, 2017 March 27, 2016 (Dollars and shares in thousands, except per share) Net revenue $ 510,705 $ 464,124 Net income $ 26,247 $ 36,186 Basic earnings per common share: Net income $ 0.58 $ 0.87 Diluted earnings per common share: Net income $ 0.56 $ 0.74 Weighted average common shares outstanding: Basic 44,893 41,647 Diluted 46,615 48,782 The unaudited pro forma combined financial information presented above includes the accounting effects of the business combination, including amortization charges from acquired intangible assets, adjustments for depreciation of property plant and equipment, interest expense, the revaluation of inventory and the related tax effects. The unaudited pro forma financial information for the three months ended April 2, 2017 includes non-recurring charges specifically related to the acquisition, including $23.8 million in combined acquisition costs of the Company and Vascular Solutions and $2.1 million in interest expense associated with a bridge loan facility that was put in place on December 1, 2016 to, among other things, assist the Company in financing the acquisition of Vascular Solutions. The bridge facility was not utilized, as the required financing was provided under the Credit Agreement. The unaudited pro forma combined financial information for the three months ended March 27, 2016 reflects the historical results of Vascular Solutions based upon their respective reporting period for the three months ended March 31, 2016 and the effects of the pro forma adjustments listed above. 2016 acquisitions The Company made the following acquisitions during 2016 (the "2016 acquisitions"), which, with the exception of its acquisition of the outstanding noncontrolling interest in Teleflex Medical Private Limited, were accounted for as business combinations: • On September 2, 2016, the Company acquired certain assets of CarTika Medical, Inc., ("CarTika"), an original equipment manufacturer (OEM) of catheters and other medical devices that complement the Company's OEM product portfolio. • On July 1, 2016, the Company, which previously owned a 74% controlling interest in its Indian affiliate, Teleflex Medical Private Limited, acquired the remaining 26% ownership interest from the noncontrolling shareholders. Teleflex Medical Private Limited is part of the Company's Asia reportable operating segment. As this acquisition did not result in a change in the Company's control of the entity, the Company recognized the $7.5 million excess of the purchase price of the noncontrolling interest over its carrying value as equity. • During the second quarter 2016, the Company acquired certain assets of two medical device and supplies distributors in New Zealand. The aggregate purchase price paid in connection with the 2016 acquisitions was $22.8 million . The results of operations of the acquired businesses and assets are included in the condensed consolidated statements of income from their respective acquisition dates. Pro forma information is not presented, as the operations of the acquired businesses are not significant to the overall operations of the Company.

Restructuring charges

Restructuring charges	3 Months Ended
	Apr. 02, 2017
Restructuring and Related Activities [Abstract]
Restructuring charges	Note 4 — Restructuring charges The restructuring charges recognized for the three months ended April 2, 2017 and March 27, 2016 consisted of the following: Three Months Ended April 2, 2017 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2017 Vascular Solutions Integration Program $ 4,482 $ — $ — $ — $ 4,482 2017 EMEA Restructuring Program 7,121 — — — 7,121 2016 Footprint realignment plan 539 12 (71 ) 29 509 2014 Footprint realignment plan 303 — — 8 311 Other restructuring programs (1) 305 47 130 40 522 Total restructuring charges $ 12,750 $ 59 $ 59 $ 77 $ 12,945 Three Months Ended March 27, 2016 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2016 Footprint realignment plan $ 10,347 $ — $ — $ — $ 10,347 Other restructuring programs (2) (495 ) 123 (108 ) 101 (379 ) Total restructuring charges $ 9,852 $ 123 $ (108 ) 101 $ 9,968 (1) Other restructuring programs include the 2016 Other Restructuring programs and the 2015 Restructuring programs. For a description of these plans, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016. (2) Other restructuring programs includes the 2015 Restructuring programs, the 2014 Footprint Realignment plan and the 2012 Restructuring program. For a description of these plans, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016. 2017 Vascular Solutions Integration Program During the first quarter 2017, the Company committed to a restructuring program related to the integration of Vascular Solutions into Teleflex. The Company initiated the program in the first quarter 2017 and expects the program to be substantially completed by the end of the second quarter 2018. The Company estimates that it will record aggregate pre-tax restructuring charges of $6.0 million to $7.5 million related to this program, of which $4.5 million to $5.3 million will constitute termination benefits, while $1.5 million to $2.2 million will relate to other exit costs including employee relocation and outplacement costs. Additionally, the Company expects to incur $2.5 million to $3.0 million of restructuring related charges consisting primarily of retention bonuses offered to certain employees expected to remain with the Company after completion of the program. All of these charges will result in future cash outlays. 2017 EMEA Restructuring Program During the first quarter 2017, the Company committed to a restructuring program to centralize certain administrative functions in Europe. The program will commence in the second quarter 2017 and is expected to be substantially completed by the end of 2018. The Company estimates that it will record aggregate pre-tax restructuring charges of $7.1 million to $8.5 million related to this program, almost all of which constitute termination benefits, and all of which will result in future cash outlays. 2016 Other Restructuring Programs During 2016, the Company committed to programs designed to improve operating efficiencies and reduce costs. The programs involve the consolidation of certain global administrative functions and manufacturing operations (the "Other 2016 restructuring programs"). The programs commenced in the second half of 2016 and are expected to be substantially complete by the end of the first quarter 2018. The Company estimates that it will record aggregate pre-tax charges of $3.8 million to $4.7 million related to these actions, substantially all of which constitute termination benefits that will result in future cash outlays. Additionally, the Company expects to incur approximately $1.5 million of accelerated depreciation and other costs directly related to these programs and anticipates that these costs to be recognized in cost of goods sold, of which, approximately $0.6 million is expected to result in future outlays. As of April 2, 2017 , the Company has a restructuring reserve of $1.7 million related to this program. 2016 Footprint Realignment Plan In 2016, the Company initiated a restructuring plan (the “2016 footprint realignment plan’) designed to reduce costs, improve operating efficiencies and enhance the Company’s long term competitive position. The plan involves the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. These actions commenced in the first quarter of 2016 and are expected to be substantially completed by the end of 2018. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2016 footprint realignment plan of between approximately $34 million to $44 million , of which an estimated $27 million to $31 million are expected to result in future cash outlays. Most of these charges, and the related cash outlays, are expected to be made prior to the end of 2018. In addition to the restructuring charges outlined in the tables above, the Company recorded restructuring related charges of $2.1 million and $0.6 million for the three months ended April 2, 2017 and March 27, 2016, respectively, related to this plan, the majority of which constituted accelerated depreciation and other costs, principally for the transfer of manufacturing operations to the new locations. These costs were recognized primarily in cost of goods sold. As of April 2, 2017 , the Company has incurred net aggregate restructuring charges related to the 2016 Footprint realignment plan of $13.0 million . Additionally, as of April 2, 2017 , the Company has incurred net aggregate accelerated depreciation and certain other costs, principally related to the transfer of manufacturing operations to new locations, of $8.5 million . These costs primarily were included in cost of goods sold. As of April 2, 2017 , the Company has a restructuring reserve of $8.9 million related to this plan, the majority of which relates to termination benefits. 2014 Footprint Realignment Plan In 2014, the Company initiated a restructuring plan (“the 2014 footprint realignment plan”) involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of 2020.The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2014 footprint realignment plan of approximately $43 million to $48 million , of which, an estimated $33 million to $38 million are expected to result in future cash outlays. These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of 2020. The Company expects to incur $24 million to $30 million in aggregate capital expenditures under the plan . In addition to the restructuring charges set forth in the tables above, the Company recorded restructuring related charges of $1.6 million and $2.1 million for the three months ended April 2, 2017 and March 27, 2016, respectively, related to the 2014 footprint realignment plan, the majority of which constituted accelerated depreciation and other costs principally related to the transfer of manufacturing operations to new locations. These costs were recognized primarily in cost of goods sold. As of April 2, 2017 , the Company has incurred net aggregate restructuring charges related to the 2014 footprint realignment plan of $11.4 million . Additionally, as of April 2, 2017 , the Company has incurred net aggregate accelerated depreciation and certain other costs, principally for the transfer of manufacturing operations from the existing locations to the new locations in connection with the plan of $24.5 million . These costs primarily were included in cost of goods sold. As of April 2, 2017 , the Company has a restructuring reserve of $4.8 million in connection with the plan, all of which relates to termination benefits. For additional information regarding the Company's restructuring programs, see Note 4 to the Company's consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016. Restructuring charges by reportable operating segment for the three months ended April 2, 2017 and March 27, 2016 are set forth in the following table: Three Months Ended April 2, 2017 March 27, 2016 (Dollars in thousands) Restructuring charges Vascular North America $ 748 $ 4,163 Anesthesia North America 247 1,875 Surgical North America — (19 ) EMEA 7,500 3,872 Asia — 2 OEM — 4 All other 4,450 71 Total restructuring charges $ 12,945 $ 9,968

Inventories, net

Inventories, net	3 Months Ended
	Apr. 02, 2017
Inventory Disclosure [Abstract]
Inventories, net	Note 5 — Inventories, net Inventories as of April 2, 2017 and December 31, 2016 consisted of the following: April 2, 2017 December 31, 2016 (Dollars in thousands) Raw materials $ 92,172 $ 65,319 Work-in-process 60,063 54,555 Finished goods 203,054 196,297 Inventories, net $ 355,289 $ 316,171

Goodwill and other intangible a

Goodwill and other intangible assets, net	3 Months Ended
	Apr. 02, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets, net	Note 6 — Goodwill and other intangible assets, net The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the three months ended April 2, 2017 : Vascular Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) Balance as of December 31, 2016 $ 345,546 $ 141,253 $ 250,912 $ 290,041 $ 138,185 $ 4,883 $ 105,900 $ 1,276,720 Goodwill related to acquisitions — — — — — — 521,396 521,396 Currency translation and other adjustments (1,590 ) 93 — 11,186 5,735 — 1,958 17,382 Balance as of April 2, 2017 $ 343,956 $ 141,346 $ 250,912 $ 301,227 $ 143,920 $ 4,883 $ 629,254 $ 1,815,498 The following table provides information as of April 2, 2017 and December 31, 2016 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net: Gross Carrying Amount Accumulated Amortization April 2, 2017 December 31, 2016 April 2, 2017 December 31, 2016 (Dollars in thousands) Customer relationships $ 885,648 $ 622,428 $ (248,033 ) $ (239,055 ) In-process research and development 32,689 16,532 — — Intellectual property 769,892 519,962 (213,843 ) (203,390 ) Distribution rights 23,185 23,021 (15,673 ) (15,239 ) Trade names 400,406 379,724 (15,357 ) (13,974 ) Non-compete agreements 2,771 2,692 (1,231 ) (1,038 ) $ 2,114,591 $ 1,564,359 $ (494,137 ) $ (472,696 )

Borrowings

Borrowings	3 Months Ended
	Apr. 02, 2017
Debt Disclosure [Abstract]
Borrowings	Note 7 — Borrowings The Company's borrowings at April 2, 2017 and December 31, 2016 were as follows: April 2, 2017 December 31, 2016 (Dollars in thousands) Senior Credit Facility: Revolving credit facility, at a rate of 2.46% at April 2, 2017, due 2022 $ 608,000 $ 210,000 Term loan facility, at a rate of 2.44% at April 2, 2017, due 2022 750,000 — 3.875% Convertible Senior Subordinated Notes due 2017 44,325 136,076 4.875% Senior Notes due 2026 400,000 400,000 5.25% Senior Notes due 2024 250,000 250,000 Securitization program, at a rate of 1.73% at April 2, 2017 50,000 50,000 2,102,325 1,046,076 Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017 (504 ) (2,707 ) Less: Unamortized debt issuance costs (12,929 ) (10,046 ) 2,088,892 1,033,323 Current borrowings (131,095 ) (183,071 ) Long-term borrowings $ 1,957,797 $ 850,252 Amended and restated senior credit facility On January 20, 2017, the Company entered into the Credit Agreement, which provides for a five year revolving credit facility of $1.0 billion and a term loan facility of $750.0 million . The obligations under the Credit Agreement are guaranteed (subject to certain exceptions and limitations) by substantially all of the material domestic subsidiaries of the Company and are secured by a lien on substantially all of the assets owned by the Company and each guarantor. The maturity date of the revolving credit facility under the Credit Agreement is January 20, 2022 and the term loan facility will mature on February 17, 2022. At the Company’s option, loans under the Credit Agreement will bear interest at a rate equal to adjusted LIBOR plus an applicable margin ranging from 1.25% to 2.50% or at an alternate base rate, which is defined as the highest of (i) the publicly announced prime rate of JPMorgan Chase Bank, N.A., the administrative agent under the Credit Agreement, (ii) 0.5% above the federal funds rate and (iii) 1% above adjusted LIBOR for a one month interest period on such day, plus an applicable margin ranging from 0.25% to 1.50% , in each case subject to adjustment based on the Company’s consolidated total leverage ratio (generally, the ratio of Consolidated Total Funded Indebtedness to Consolidated EBITDA, each as defined in the Credit Agreement, for the four most recent fiscal quarters ending on or preceding the date of determination). Overdue loans will bear interest at the rate otherwise applicable to such loans plus 2.00% . The Company is required to maintain a maximum total consolidated leverage ratio of 4.50 to to 1.00 and a maximum consolidated senior secured leverage ratio (generally, Consolidated Senior Secured Funded Indebtedness, as defined in the Credit Agreement, on the date of determination to Consolidated EBITDA for the four most recent quarters ending on or preceding the date of determination) of 3.50 to 1.00. The Company is further required to maintain a consolidated interest coverage ratio (generally, Consolidated EBITDA for the four most recent fiscal quarters ending on or preceding the date of determination to Consolidated Interest Expense, as defined in the Credit Agreement, paid in cash for such period) of not less than 3.50 to 1.00. The Company capitalized $12.0 million related to transaction fees, including underwriters’ discounts and commissions, incurred in connection with the Credit Agreement. In addition, because the Company's entry into the Credit Agreement was considered a partial extinguishment of the indebtedness under its previously outstanding credit agreement, the Company recognized a loss on extinguishment of debt of $0.4 million for three months ended April 2, 2017 . 3.875% Convertible Senior Subordinated Note s - Exchange Transactions On January 5, 2017, pursuant to separate, privately negotiated agreements between the Company and certain holders (the "Holders") of its 3.875% Convertible Senior Subordinated Notes due 2017 (the "Convertible Notes"), the Company paid cash and common stock (the "Exchange Consideration") to the Holders in exchange for $91.7 million aggregate principal amount of the Convertible Notes (the "Exchange Transactions"). The Exchange Consideration paid to each of the Holders per $1,000 principal amount of Convertible Notes was equal to: (i) $1,000 in cash, (ii) a number of shares of the Company's common stock equal to the amount of the conversion value of the Convertible Notes in excess of the $1,000 principal amount (the "Conversion Shares"), calculated on the basis of the average daily volume weighted average price per share of Company common stock over a specified period (the "Average Daily VWAP"), (iii) an inducement payment in additional shares of common stock (the "Inducement Shares") calculated based on the Average Daily VWAP; and (iv) cash in an amount equal to accrued and unpaid interest to, but not including, the closing date. As a result of the Exchange Transactions, the Company paid the Holders aggregate cash consideration of approximately $93.2 million (which includes approximately $1.5 million in accrued but previously unpaid interest) and issued and delivered to the Holders approximately 0.93 million shares of Company common stock (including both Conversion Shares and Inducement Shares). The Company funded the $93.2 million cash payment constituting part of the Exchange Consideration through borrowings under its revolving credit facility. As a result of the Exchange Transactions, the Company recognized a loss on extinguishment of debt of $5.2 million . In connection with its entry into the Exchange Transactions, the Company also entered into bond hedge unwind agreements (the "Hedge Unwind Agreements") and warrant unwind agreements (the "Warrant Unwind Agreements") with the dealer counterparties to the convertible note hedge transactions and warrant transactions that were effected at the time of the initial issuance of the Convertible Notes. Under the Hedge Unwind Agreements, the number of then-outstanding call options issued to the Company under the Convertible Note hedge transactions was reduced to reflect proportionately the reduction in the outstanding principal amount of the Convertible Notes following the Exchange Transactions. Under the Warrant Unwind Agreements, the number of warrants then held by the dealer counterparties also was reduced. On a net basis, after giving effect to the Hedge Unwind Agreements and Warrant Unwind Agreements, the Company received 0.12 million shares of Company common stock from the dealer counterparties. Fair Value of Long-Term Borrowings To determine the fair value of the debt categorized as Level 2 in the table below, the Company uses a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. The Company’s implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of the Company’s debt as of April 2, 2017 and December 31, 2016 , categorized by the level of inputs within the fair value hierarchy used to measure fair value (see Note 10, “Fair value measurement,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 for further information regarding the fair value hierarchy): April 2, 2017 December 31, 2016 (Dollars in thousands) Level 1 $ 140,389 $ 344,765 Level 2 2,015,793 929,362 Total $ 2,156,182 $ 1,274,127

Financial instruments

Financial instruments	3 Months Ended
	Apr. 02, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial instruments	Note 8 — Financial instruments Foreign Currency Forward Contracts The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage exposure related to foreign currency transactions. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage near term foreign currency denominated monetary assets and liabilities. For the three months ended April 2, 2017 and March 27, 2016, the Company recognized a loss related to non-designated foreign currency forward contracts of $0.8 million and $0.3 million , respectively. The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of April 2, 2017 and December 31, 2016 : April 2, 2017 December 31, 2016 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 2,054 $ 667 Non-designated foreign currency forward contracts 152 490 Prepaid expenses and other current assets $ 2,206 $ 1,157 Total asset derivatives $ 2,206 $ 1,157 Liability derivatives: Designated foreign currency forward contracts $ 1,589 $ 2,139 Non-designated foreign currency forward contracts 303 118 Other current liabilities $ 1,892 $ 2,257 Total liability derivatives $ 1,892 $ 2,257 The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of April 2, 2017 and December 31, 2016 was $124.4 million and $101.8 million , respectively. The total notional amount for all open non-designated foreign currency forward contracts as of April 2, 2017 and December 31, 2016 was $79.3 million and $73.4 million , respectively. All open foreign currency forward contracts as of April 2, 2017 have durations of twelve months or less. The following table provides information as to the gains and losses attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (loss) (“OCI”) for the three months ended April 2, 2017 and March 27, 2016 : After Tax Gain (Loss) Recognized in OCI Three Months Ended April 2, 2017 March 27, 2016 (Dollars in thousands) Foreign currency forward contracts $ 1,728 $ 1,480 See Note 10 for information on the location in the condensed consolidated statements of income and amount of losses/(gains) attributable to derivatives that were reclassified from accumulated other comprehensive income (“AOCI”) to expense (income), net of tax. There was no ineffectiveness related to the Company’s cash flow hedges during the three months ended April 2, 2017 and March 27, 2016 . Concentration of Credit Risk Concentrations of credit risk with respect to trade accounts receivable are generally limited due to the Company’s large number of customers and their diversity across many geographic areas. A portion of the Company’s trade accounts receivable outside the United States, however, include sales to government-owned or supported healthcare systems in several countries which are subject to payment delays. Payment is dependent upon the creditworthiness of those countries and the financial stability of their economies. Certain of the Company’s customers, particularly in Greece, Italy, Spain and Portugal, have extended or delayed payments for products and services already provided, raising collectability concerns regarding the Company’s accounts receivable from these customers. As a result, the Company continues to closely monitor the allowance for doubtful accounts with respect to these customers. The following table shows the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at April 2, 2017 and December 31, 2016 : April 2, 2017 December 31, 2016 (Dollars in thousands) Allowance for doubtful accounts (1) $ 9,188 $ 8,630 Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal (2) $ 46,272 $ 51,098 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 16.4 % 19.3 % (1) The current portion of the allowance for doubtful accounts was $2.1 million and $2.0 million as of April 2, 2017 and December 31, 2016, respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at April 2, 2017 and December 31, 2016 was $3.2 million and $2.7 million , respectively In January 2017, the Company sold $16.1 million of receivables outstanding with respect to publicly funded hospitals in Italy for $16.0 million . For the three months ended April 2, 2017 and March 27, 2016 , net revenues from customers in Greece, Italy, Spain and Portugal were $31.5 million and $30.9 million , respectively.

Fair value measurement

Fair value measurement	3 Months Ended
	Apr. 02, 2017
Fair Value Disclosures [Abstract]
Fair value measurement	Note 9 — Fair value measurement For a description of the fair value hierarchy, see Note 10 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2016 . The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of April 2, 2017 and December 31, 2016 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 8,048 $ 8,048 $ — $ — Derivative assets 2,206 — 2,206 — Derivative liabilities 1,892 — 1,892 — Contingent consideration liabilities (1) 7,202 — — 7,202 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 7,660 $ 7,660 $ — $ — Derivative assets 1,157 — 1,157 — Derivative liabilities 2,257 — 2,257 — Contingent consideration liabilities (1) 7,102 — — 7,102 (1) As of April 2, 2017 and December 31, 2016, $0.7 million and $0.6 million was recorded as the current portion of contingent consideration, respectively, and $6.5 million was recognized in other liabilities in the condensed consolidated balance sheet. There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the three months ended April 2, 2017 . The following table provides information regarding changes, during the three months ended April 2, 2017 , in Level 3 financial liabilities related to contingent consideration, which are described below in this Note 9 under "Valuation Techniques": Contingent consideration 2017 (Dollars in thousands) Balance - December 31, 2016 $ 7,102 Payment (79 ) Revaluations 179 Balance - April 2, 2017 $ 7,202 Valuation Techniques The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses foreign currency forward contracts to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. The Company measures the fair value of the foreign currency forward contracts by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties. The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions. The Company determines the fair value of the liabilities for contingent consideration based on discounted cash flow analysis. This fair value measurement is based on significant inputs unobservable in the market, primarily estimated sales royalties and the discount rate and, therefore, constitutes a Level 3 measurement within the fair value hierarchy.

Shareholders' equity

Shareholders' equity	3 Months Ended
	Apr. 02, 2017
Equity [Abstract]
Shareholders' equity	Note 10 — Shareholders’ equity Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average shares outstanding: Three Months Ended April 2, 2017 March 27, 2016 (Shares in thousands) Basic 44,893 41,647 Dilutive effect of share-based awards 821 519 Dilutive effect of 3.875% Convertible Notes and warrants (1) 901 6,616 Diluted 46,615 48,782 (1) The reduction in the dilutive effect of the Convertible Notes and warrants at April 2, 2017 as compared to March 27, 2016 is due to the Company’s repurchase of Convertible Notes and conversions by holders of the Convertible Notes subsequent to March 27, 2016. Weighted average shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.5 million and 5.2 million for the three months ended April 2, 2017 and March 27, 2016 , respectively. In connection with the issuance of the Convertible Notes, the Company entered into convertible note hedge and warrant agreements. The convertible note hedge, consisting of call options held by the Company, economically reduces the dilutive impact of the Convertible Notes. However, applicable accounting guidance requires the Company to separately address the dilutive impact of the warrants issued under the warrant agreements in computing diluted weighted average shares outstanding, without giving effect to the anti-dilutive impact of the call options. The reduction in the number of diluted shares that would result from giving effect to the anti-dilutive impact of the call options would have been 0.5 million and 3.6 million for the three months ended April 2, 2017 and March 27, 2016 , respectively. The treasury stock method is applied to the warrants because the average market price of the Company's common stock during the reporting periods presented exceeds the warrant exercise price of $74.65 per share, and assumes the proceeds from the exercise of the warrants are used by the Company to repurchase shares based on such average market price. Shares issuable upon exercise of the warrants that were included in the total diluted shares outstanding were 0.4 million and 3.0 million for the three months ended April 2, 2017 and March 27, 2016 , respectively. The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the three months ended April 2, 2017 and March 27, 2016 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive income (loss) before reclassifications 350 (241 ) 46,982 47,091 Amounts reclassified from accumulated other comprehensive income 1,378 1,131 — 2,509 Net current-period other comprehensive income 1,728 890 46,982 49,600 Balance as of April 2, 2017 $ (696 ) $ (135,706 ) $ (252,715 ) $ (389,117 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2015 $ (2,491 ) $ (138,887 ) $ (229,746 ) $ (371,124 ) Other comprehensive (loss) before reclassifications (50 ) 182 20,476 20,608 Amounts reclassified from accumulated other comprehensive loss 1,530 1,056 — 2,586 Net current-period other comprehensive income 1,480 1,238 20,476 23,194 Balance at March 27, 2016 $ (1,011 ) $ (137,649 ) $ (209,270 ) $ (347,930 ) The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three months ended April 2, 2017 and March 27, 2016 : Three Months Ended April 2, 2017 March 27, 2016 (Dollars in thousands) Losses on foreign exchange contracts: Cost of goods sold $ 1,645 $ 1,871 Total before tax 1,645 1,871 Tax benefit (267 ) (341 ) Net of tax $ 1,378 $ 1,530 Amortization of pension and other postretirement benefit items: Actuarial losses (1) $ 1,726 $ 1,622 Prior-service costs (1) 29 14 Total before tax 1,755 1,636 Tax benefit (624 ) (580 ) Net of tax $ 1,131 $ 1,056 Total reclassifications, net of tax $ 2,509 $ 2,586 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information). Mezzanine Equity As of December 31, 2016, the Company reclassified $1.8 million from additional paid-in capital to convertible notes in the mezzanine equity section of the Company's consolidated balance sheet. The reclassified amount represents the aggregate difference between the principal amount and the carrying value of the Convertible Notes purchased by the Company pursuant to the Exchange Transactions (see "3.875% Convertible Senior Subordinated Notes - Exchange Transactions" within Note 7) under agreements that were entered into prior to December 31,2016, but not consummated until January 5, 2017 . No reclassification was required as of April 2, 2017 .

Taxes on income from continuing

Taxes on income from continuing operations	3 Months Ended
	Apr. 02, 2017
Income Tax Disclosure [Abstract]
Taxes on income from continuing operations	Note 11 — Taxes on income from continuing operations Three Months Ended April 2, 2017 March 27, 2016 Effective income tax rate (7.1)% 4.9% The effective income tax rate for the three months ended April 2, 2017 and March 27, 2016 was (7.1)% and 4.9% , respectively. The effective income tax rate for the three months ended April 2, 2017 , as compared to the first quarter 2016, reflects an excess tax benefit associated with share based payments, recognized under the new FASB guidance adopted by the Company as of January 1, 2017. In addition, the Company recognized discrete tax benefits associated the acquisition of Vascular Solutions. The effective tax rate for the three months ended March 27, 2016 reflects a tax benefit on the settlement of a foreign tax audit.

Pension and other postretiremen

Pension and other postretirement benefits	3 Months Ended
	Apr. 02, 2017
Compensation and Retirement Disclosure [Abstract]
Pension and other postretirement benefits	Note 12 — Pension and other postretirement benefits The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. As of April 2, 2017 , no further benefits are being accrued under the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement. Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits April 2, 2017 March 27, 2016 April 2, 2017 March 27, 2016 (Dollars in thousands) Service cost $ 717 $ 652 $ 74 $ 111 Interest cost 3,785 3,920 378 406 Expected return on plan assets (6,743 ) (6,198 ) — — Net amortization and deferral 1,690 1,579 65 57 Net benefits expense (income) $ (551 ) $ (47 ) $ 517 $ 574

Commitments and contingent liab

Commitments and contingent liabilities	3 Months Ended
	Apr. 02, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Note 13 — Commitments and contingent liabilities Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At April 2, 2017 , the Company has recorded $1.1 million and $5.6 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of April 2, 2017 . The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 15 - 20 years. Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment, environmental and other matters. As of April 2, 2017 , the Company has recorded accrued liabilities of $2.4 million in connection with such contingencies, representing its best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Of the amount accrued as of April 2, 2017 , $1.7 million pertains to discontinued operations. During the first quarter 2017, Teleflex Medical Trading (Shanghai) Company, Ltd. (“Teleflex Shanghai”), one of the Company’s subsidiaries, eliminated a key distributor within its sales channel in China and undertook a distributor to direct sales conversion within that channel. On March 24, 2017, the distributor submitted an application for arbitration alleging, among other things, that Teleflex Shanghai wrongfully terminated its relationship with the distributor. The distributor is seeking $10.1 million (RMB 69.3 million ) in damages for alleged costs of transportation and dismissal of personnel, as well as lost estimated profits. In addition, the distributor is seeking to compel Teleflex Shanghai to repurchase, for $9.1 million (RMB 63.0 million ), Teleflex products that the distributor alleges are currently held in its inventory. Teleflex Shanghai intends to vigorously contest the distributor’s arbitration claim, and has filed a counterclaim seeking payment from the distributor of $8.9 million (RMB 61.2 million ) in respect of outstanding trade receivables owed by the distributor to Teleflex Shanghai. At this time, the Company is unable to make an estimate of the amount of loss, if any, or range of possible loss that the Company could incur as a result of this matter. In 2006, the Company was named as a defendant in a wrongful death product liability lawsuit filed in the Louisiana State District Court for the Parish of Calcasieu, involving a product manufactured by the Company’s former marine business. In September 2014, the case was tried before a jury, which returned a verdict in favor of the Company. The plaintiff subsequently filed a motion for a new trial, which was granted, and the case was re-tried before a jury in December 2014. On December 5, 2014, the jury returned a verdict in favor of the plaintiff, awarding $0.1 million in compensatory damages and $23.0 million in punitive damages, plus pre- and post-judgment interest on the compensatory damages and post-judgment interest on the punitive damages. The Company filed an appeal with the Louisiana Court of Appeal, and the plaintiff filed a cross-appeal, seeking to overturn the trial court’s denial of pre-judgment interest on the punitive damages award. On June 29, 2016, the Louisiana Court of Appeal affirmed the trial court verdict in all respects. The Company and the plaintiff filed applications for a writ of certiorari (a request for review) to the Louisiana Supreme Court. On January 13, 2017, the Louisiana Supreme Court granted the Company's writ application. Oral arguments were held on May 1, 2017 and the parties currently are awaiting the court’s decision. As of April 2, 2017 , the Company has accrued a liability representing its best estimate of probable loss associated with this matter, which is included in the Company’s accrued liabilities for litigation matters relating to discontinued operations discussed in the preceding paragraph. The Company believes that any liability arising from this matter that is not covered by the Company's product liability insurance will not exceed $10.0 million . Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various tax authorities. As of April 2, 2017 , the most significant tax examinations in process are in Canada and Germany. The Company may establish reserves with respect to its uncertain tax positions, after which it adjusts its reserves to address developments with respect to these uncertain tax positions. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results. Other: The Company has various purchase commitments for materials, supplies and other items occurring in the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Segment information

Segment information	3 Months Ended
	Apr. 02, 2017
Segment Reporting [Abstract]
Segment information	Note 14 — Segment information The following tables present the Company’s segment results for the three months ended April 2, 2017 and March 27, 2016 : Three Months Ended April 2, 2017 March 27, 2016 (Dollars in thousands) Revenue Vascular North America $ 93,849 $ 81,588 Anesthesia North America 48,207 45,957 Surgical North America 45,944 38,941 EMEA 130,733 122,095 Asia 48,953 49,156 OEM 43,346 33,977 All other 76,849 53,179 Consolidated net revenues $ 487,881 $ 424,893 Three Months Ended April 2, 2017 March 27, 2016 (Dollars in thousands) Operating profit Vascular North America $ 24,816 $ 19,656 Anesthesia North America 13,527 12,177 Surgical North America 16,380 13,256 EMEA 22,240 21,043 Asia 10,798 13,008 OEM 9,121 5,189 All other (6,301 ) 5,743 Total segment operating profit (1) 90,581 90,072 Unallocated expenses (2) (29,762 ) (22,575 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 60,819 $ 67,497 (1) Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.

Condensed consolidating guarant

Condensed consolidating guarantor financial information	3 Months Ended
	Apr. 02, 2017
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed consolidating guarantor financial information	Note 15 — Condensed consolidating guarantor financial information Teleflex Incorporated (the "Parent Company") is the issuer of its 5.25% Senior Notes due 2024 (the "2024 Notes") and 4.875% Senior Notes due 2026 (the "2026 Notes"). Payment of the Parent Company's obligations under the 2024 Notes and 2026 Notes is guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income for the three months ended April 2, 2017 and March 27, 2016 , condensed consolidating balance sheets as of April 2, 2017 and December 31, 2016 and condensed consolidating statements of cash flows for the three months ended April 2, 2017 and March 27, 2016 , provide consolidated information for: a. Parent Company, the issuer of the guaranteed obligations; b. Guarantor Subsidiaries, on a combined basis; c. Non-Guarantor Subsidiaries (i.e., those subsidiaries of the Parent Company that have not guaranteed payment of the 2024 Notes and 2026 Notes), on a combined basis; and d. Parent Company and its subsidiaries on a consolidated basis. The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidating financial information, except for the use of the equity method of accounting to reflect ownership interests in subsidiaries, which are eliminated upon consolidation. Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries. TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) Three Months Ended April 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 315,643 $ 276,315 $ (104,077 ) $ 487,881 Cost of goods sold — 192,001 143,896 (103,576 ) 232,321 Gross profit — 123,642 132,419 (501 ) 255,560 Selling, general and administrative expenses 20,519 94,043 48,844 563 163,969 Research and development expenses 235 11,186 6,406 — 17,827 Restructuring charges — 5,374 7,571 — 12,945 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (20,754 ) 13,039 69,598 (1,064 ) 60,819 Interest, net 47,674 (30,963 ) 846 — 17,557 Loss on extinguishment of debt 5,582 — — — 5,582 (Loss) income from continuing operations before taxes (74,010 ) 44,002 68,752 (1,064 ) 37,680 (Benefit) taxes on (loss) income from continuing operations (29,907 ) 14,485 12,229 524 (2,669 ) Equity in net income of consolidated subsidiaries 84,452 55,802 216 (140,470 ) — Income from continuing operations 40,349 85,319 56,739 (142,058 ) 40,349 Operating loss from discontinued operations (282 ) — — — (282 ) Benefit on loss from discontinued operations (103 ) — — — (103 ) Loss from discontinued operations (179 ) — — — (179 ) Net income 40,170 85,319 56,739 (142,058 ) 40,170 Other comprehensive income 49,600 49,404 53,901 (103,305 ) 49,600 Comprehensive income $ 89,770 $ 134,723 $ 110,640 $ (245,363 ) $ 89,770 Three Months Ended March 27, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 258,911 $ 261,348 $ (95,366 ) $ 424,893 Cost of goods sold — 155,541 132,963 (88,758 ) 199,746 Gross profit — 103,370 128,385 (6,608 ) 225,147 Selling, general and administrative expenses 9,329 81,477 45,059 483 136,348 Research and development expenses — 6,435 5,918 — 12,353 Restructuring charges — 4,758 5,210 — 9,968 Gain on sale of assets — — (1,019 ) — (1,019 ) (Loss) income from continuing operations before interest and taxes (9,329 ) 10,700 73,217 (7,091 ) 67,497 Interest, net 33,044 (20,318 ) 978 — 13,704 (Loss) income from continuing operations before taxes (42,373 ) 31,018 72,239 (7,091 ) 53,793 (Benefit) taxes on (loss) income from continuing operations (15,848 ) 11,677 7,864 (1,080 ) 2,613 Equity in net income of consolidated subsidiaries 77,457 57,900 168 (135,525 ) — Income from continuing operations 50,932 77,241 64,543 (141,536 ) 51,180 Operating loss from discontinued operations (382 ) — — — (382 ) (Benefit) taxes on loss from discontinued operations (139 ) — 69 — (70 ) Loss from discontinued operations (243 ) — (69 ) — (312 ) Net income 50,689 77,241 64,474 (141,536 ) 50,868 Less: Income from continuing operations attributable to noncontrolling interest — — 179 — 179 Net income attributable to common shareholders 50,689 77,241 64,295 (141,536 ) 50,689 Other comprehensive income attributable to common shareholders 23,194 18,573 22,412 (40,985 ) 23,194 Comprehensive income attributable to common shareholders $ 73,883 $ 95,814 $ 86,707 $ (182,521 ) $ 73,883 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS April 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 153,100 $ 7,593 $ 528,436 $ — $ 689,129 Accounts receivable, net 2,215 34,464 241,897 4,296 282,872 Accounts receivable from consolidated subsidiaries 8,025 2,238,256 338,230 (2,584,511 ) — Inventories, net — 222,619 158,358 (25,688 ) 355,289 Prepaid expenses and other current assets 14,084 9,477 20,340 3,337 47,238 Prepaid taxes 11,072 — 9,527 — 20,599 Total current assets 188,496 2,512,409 1,296,788 (2,602,566 ) 1,395,127 Property, plant and equipment, net 2,517 207,818 144,899 — 355,234 Goodwill — 1,228,353 587,145 — 1,815,498 Intangibles assets, net — 1,167,974 452,480 — 1,620,454 Deferred tax assets 72,621 — 5,434 (76,092 ) 1,963 Notes receivable and other amounts due from consolidated subsidiaries 1,321,595 2,151,605 — (3,473,200 ) — Other assets 7,203,940 1,578,527 30,859 (8,769,166 ) 44,160 Total assets $ 8,789,169 $ 8,846,686 $ 2,517,605 $ (14,921,024 ) $ 5,232,436 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 81,095 $ — $ 50,000 $ — $ 131,095 Accounts payable 4,335 40,095 37,588 — 82,018 Accounts payable to consolidated subsidiaries 2,290,413 255,530 38,568 (2,584,511 ) — Accrued expenses 19,473 26,116 36,801 — 82,390 Current portion of contingent consideration — 669 — — 669 Payroll and benefit-related liabilities 16,858 15,707 33,362 — 65,927 Accrued interest 12,657 — 29 — 12,686 Income taxes payable — — 7,519 524 8,043 Other current liabilities 1,926 4,153 3,451 — 9,530 Total current liabilities 2,426,757 342,270 207,318 (2,583,987 ) 392,358 Long-term borrowings 1,957,797 — — — 1,957,797 Deferred tax liabilities — 504,454 32,292 (76,092 ) 460,654 Pension and postretirement benefit liabilities 82,623 31,223 16,380 — 130,226 Noncurrent liability for uncertain tax positions 1,432 13,731 2,776 — 17,939 Notes payable and other amounts due to consolidated subsidiaries 2,076,792 1,203,358 193,050 (3,473,200 ) — Other liabilities 24,864 15,770 13,924 — 54,558 Total liabilities 6,570,265 2,110,806 465,740 (6,133,279 ) 3,013,532 Total shareholders' equity 2,218,904 6,735,880 2,051,865 (8,787,745 ) 2,218,904 Total liabilities and shareholders' equity $ 8,789,169 $ 8,846,686 $ 2,517,605 $ (14,921,024 ) $ 5,232,436 December 31, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 14,571 $ 1,031 $ 528,187 $ — $ 543,789 Accounts receivable, net 2,551 8,768 255,815 4,859 271,993 Accounts receivable from consolidated subsidiaries 4,861 2,176,059 309,149 (2,490,069 ) — Inventories, net — 200,852 140,406 (25,087 ) 316,171 Prepaid expenses and other current assets 14,239 5,332 17,474 3,337 40,382 Prepaid taxes — — 7,766 413 8,179 Assets held for sale — — 2,879 — 2,879 Total current assets 36,222 2,392,042 1,261,676 (2,506,547 ) 1,183,393 Property, plant and equipment, net 2,566 163,847 136,486 — 302,899 Goodwill — 708,546 568,174 — 1,276,720 Intangibles assets, net — 640,999 450,664 — 1,091,663 Deferred tax assets 73,051 — 5,185 (76,524 ) 1,712 Notes receivable and other amounts due from consolidated subsidiaries 1,387,615 2,085,538 — (3,473,153 ) — Other assets 6,044,337 1,525,285 29,962 (7,564,758 ) 34,826 Total assets $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 133,071 $ — $ 50,000 $ — $ 183,071 Accounts payable 4,540 30,924 33,936 — 69,400 Accounts payable to consolidated subsidiaries 2,242,814 214,203 33,052 (2,490,069 ) — Accrued expenses 16,827 18,126 30,196 — 65,149 Current portion of contingent consideration — 587 — — 587 Payroll and benefit-related liabilities 20,610 26,672 35,397 — 82,679 Accrued interest 10,429 — 21 — 10,450 Income taxes payable 1,246 — 6,577 85 7,908 Other current liabilities 2,262 3,643 2,497 — 8,402 Total current liabilities 2,431,799 294,155 191,676 (2,489,984 ) 427,646 Long-term borrowings 850,252 — — — 850,252 Deferred tax liabilities — 316,526 31,375 (76,524 ) 271,377 Pension and postretirement benefit liabilities 85,645 31,561 15,856 — 133,062 Noncurrent liability for uncertain tax positions 1,169 13,684 2,667 — 17,520 Notes payable and other amounts due to consolidated subsidiaries 2,011,737 1,264,004 197,412 (3,473,153 ) — Other liabilities 23,848 15,695 12,472 — 52,015 Total liabilities 5,404,450 1,935,625 451,458 (6,039,661 ) 1,751,872 Convertible notes - redeemable equity component 1,824 — — — 1,824 Mezzanine equity 1,824 — — — 1,824 Total shareholders' equity 2,137,517 5,580,632 2,000,689 (7,581,321 ) 2,137,517 Total liabilities and shareholders' equity $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Three Months Ended April 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (86,020 ) $ 158,343 $ 80,535 $ (61,918 ) $ 90,940 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (155 ) (2,206 ) (10,533 ) — (12,894 ) Proceeds from sale of assets — — 6,332 — 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — — — (975,524 ) Net cash used in investing activities from continuing operations (975,679 ) (2,206 ) (4,201 ) — (982,086 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,194,500 — — — 1,194,500 Reduction in borrowings (138,251 ) — — — (138,251 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts (505 ) — — — (505 ) Payments for contingent consideration — (79 ) — — (79 ) Dividends paid (15,287 ) — — — (15,287 ) Intercompany transactions 179,151 (149,496 ) (29,655 ) — — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 1,200,494 (149,575 ) (91,573 ) 61,918 1,021,264 Cash flows from discontinued operations: Net cash used in operating activities (266 ) — — — (266 ) Net cash used in discontinued operations (266 ) — — — (266 ) Effect of exchange rate changes on cash and cash equivalents — — 15,488 — 15,488 Net increase in cash and cash equivalents 138,529 6,562 249 145,340 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 153,100 $ 7,593 $ 528,436 $ — $ 689,129 Three Months Ended March 27, 2016 Parent Guarantor Non-Guarantor Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (18,852 ) $ 25,624 $ 60,060 $ 66,832 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (5 ) (3,470 ) (4,347 ) (7,822 ) Proceeds from sale of assets — — 1,251 1,251 Net cash used in investing activities from continuing operations (5 ) (3,470 ) (3,096 ) (6,571 ) Cash flows from financing activities of continuing operations: Reduction in borrowings (9 ) — — (9 ) Net proceeds from share based compensation plans and the related tax impacts 3,180 — — 3,180 Payments for contingent consideration — (61 ) — (61 ) Dividends paid (14,179 ) — — (14,179 ) Intercompany transactions 32,371 (21,088 ) (11,283 ) — Net cash provided by (used in) financing activities from continuing operations 21,363 (21,149 ) (11,283 ) (11,069 ) Cash flows from discontinued operations: Net cash used in operating activities (126 ) — — (126 ) Net cash used in discontinued operations (126 ) — — (126 ) Effect of exchange rate changes on cash and cash equivalents — — 5,126 5,126 Net increase in cash and cash equivalents 2,380 1,005 50,807 54,192 Cash and cash equivalents at the beginning of the period 21,612 — 316,754 338,366 Cash and cash equivalents at the end of the period $ 23,992 $ 1,005 $ 367,561 $ 392,558

New accounting standards (Polic

New accounting standards (Policies)	3 Months Ended
	Apr. 02, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards In May 2014, the FASB, in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. The new guidance is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective for annual periods beginning after December 15, 2017 and interim periods within those years. Although the Company's evaluation of this guidance is ongoing, the Company's preliminary assessment indicates that the adoption of this guidance will not have a material impact on the Company’s results of operations, cash flows and financial position. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; the guidance provides certain practical expedients. The Company is currently evaluating this guidance to determine its impact on the Company’s results of operations, cash flows and financial position. In March 2016, the FASB issued new guidance designed to simplify several aspects of the accounting for share-based payment transactions, including, among other things, guidance related to accounting for income taxes, modification of the criteria for classification of awards as either equity awards or liability awards where an employer withholds shares from an employee's share-based award for tax withholding purposes, and classification on the statement of cash flows of cash payments to a tax authority by an employer that withholds shares from an employee's award for tax withholding purposes. The Company adopted this standard as of January 1, 2017. The Company has applied the new guidance requiring recognition of excess tax deficiencies and tax benefits in the income statement, rather than in additional paid-in-capital, as previously required. The adoption of the new standard increased net income and cash flows from operating activities by $3.4 million ( $0.07 diluted earnings per share) for the three months ended April 2, 2017. The Company will continue to estimate forfeitures of share-based awards at the time of grant, rather than recognize actual forfeitures as they occur, as permitted under the new guidance. In August 2016, the FASB issued new guidance with regard to eight specific issues pertaining to the classification of certain cash receipts and cash payments within the statement of cash flows. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. The new guidance should generally be adopted using a retrospective transition method for each period presented. Although the Company's evaluation of this guidance is ongoing, the Company's preliminary assessment indicates that the adoption of this guidance will not have a material impact on the Company's cash flows. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The guidance is effective for annual periods beginning after December 15, 2017, and early adoption is permitted as of the beginning of an annual reporting period. The guidance should be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the annual period of adoption. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In January 2017, the FASB issued new guidance to clarify the definition of a “business,” with the objective of assisting entities in evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or as an acquisition of a business. The definition of a business affects many areas of accounting, including acquisitions, disposals, goodwill and consolidation. The guidance generally defines a business as an integrated set of activities and assets (collectively referred to as a “set”) that is capable of being conducted and managed for the purpose of providing a return to investors or other owners, members, or participants. The guidance further provides that, to be considered a business, a set must meet specified requirements. However, the guidance also states that, if substantially all of the fair value of gross assets acquired (subject to specified exceptions) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not considered a business and no further analysis is required. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early application is permitted under specified circumstances. In January 2017, the FASB issued guidance to simplify the quantitative test for goodwill impairment. Under current guidance, if a reporting unit’s carrying value exceeds its fair value, the entity must determine the implied value of goodwill. This determination is made by deducting the fair value of a reporting unit’s identifiable assets and liabilities from the fair value of the reporting unit as a whole as if the reporting unit had just been acquired. Under the new guidance, a determination of the implied value of goodwill will no longer be required; a goodwill impairment will be equal to the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The revised guidance is effective for fiscal years, and any interim goodwill impairment tests within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial position or results of operations. In March 2017, the FASB issued new guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The new guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017 and generally is required to be applied retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated results of operations. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Apr. 02, 2017
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table presents the preliminary fair value determination of the assets acquired and liabilities assumed as of February 17, 2017 with respect to the Vascular Solutions acquisition, which was accounted for as a business combination: (Dollars in thousands) Assets Current assets $ 64,232 Property, plant and equipment 46,886 Intangible assets 539,250 Goodwill 521,396 Other assets 728 Total assets acquired 1,172,492 Less: Current liabilities 13,470 Deferred tax liabilities 183,498 Liabilities assumed 196,968 Net assets acquired $ 975,524
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The following table sets forth the components of identifiable intangible assets acquired and the ranges of the useful lives as of the date of acquisition: Fair value Useful life range (Dollars in thousands) (Years) Intellectual property 248,200 10- 20 In-process research and development ("IPR&D") 15,600 Indefinite Trade names 16,650 20 Customer lists 258,800 25
Business Acquisition, Pro Forma Information	The following unaudited pro forma combined financial information for the three months ended April 2, 2017 and March 27, 2016, respectively, gives effect to the Vascular Solutions acquisition as if it was completed at the beginning of each of the respective periods. Three Months Ended April 2, 2017 March 27, 2016 (Dollars and shares in thousands, except per share) Net revenue $ 510,705 $ 464,124 Net income $ 26,247 $ 36,186 Basic earnings per common share: Net income $ 0.58 $ 0.87 Diluted earnings per common share: Net income $ 0.56 $ 0.74 Weighted average common shares outstanding: Basic 44,893 41,647 Diluted 46,615 48,782

Restructuring charges (Tables)

Restructuring charges (Tables)	3 Months Ended
	Apr. 02, 2017
Restructuring and Related Activities [Abstract]
Restructuring and Other Impairment Charges	Restructuring charges by reportable operating segment for the three months ended April 2, 2017 and March 27, 2016 are set forth in the following table: Three Months Ended April 2, 2017 March 27, 2016 (Dollars in thousands) Restructuring charges Vascular North America $ 748 $ 4,163 Anesthesia North America 247 1,875 Surgical North America — (19 ) EMEA 7,500 3,872 Asia — 2 OEM — 4 All other 4,450 71 Total restructuring charges $ 12,945 $ 9,968 The restructuring charges recognized for the three months ended April 2, 2017 and March 27, 2016 consisted of the following: Three Months Ended April 2, 2017 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2017 Vascular Solutions Integration Program $ 4,482 $ — $ — $ — $ 4,482 2017 EMEA Restructuring Program 7,121 — — — 7,121 2016 Footprint realignment plan 539 12 (71 ) 29 509 2014 Footprint realignment plan 303 — — 8 311 Other restructuring programs (1) 305 47 130 40 522 Total restructuring charges $ 12,750 $ 59 $ 59 $ 77 $ 12,945 Three Months Ended March 27, 2016 Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total (Dollars in thousands) 2016 Footprint realignment plan $ 10,347 $ — $ — $ — $ 10,347 Other restructuring programs (2) (495 ) 123 (108 ) 101 (379 ) Total restructuring charges $ 9,852 $ 123 $ (108 ) 101 $ 9,968 (1) Other restructuring programs include the 2016 Other Restructuring programs and the 2015 Restructuring programs. For a description of these plans, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016. (2) Other restructuring programs includes the 2015 Restructuring programs, the 2014 Footprint Realignment plan and the 2012 Restructuring program. For a description of these plans, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016.

Inventories, net (Tables)

Inventories, net (Tables)	3 Months Ended
	Apr. 02, 2017
Inventory Disclosure [Abstract]
Inventories, net	Inventories as of April 2, 2017 and December 31, 2016 consisted of the following: April 2, 2017 December 31, 2016 (Dollars in thousands) Raw materials $ 92,172 $ 65,319 Work-in-process 60,063 54,555 Finished goods 203,054 196,297 Inventories, net $ 355,289 $ 316,171

Goodwill and other intangible28

Goodwill and other intangible assets, net (Tables)	3 Months Ended
	Apr. 02, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the three months ended April 2, 2017 : Vascular Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) Balance as of December 31, 2016 $ 345,546 $ 141,253 $ 250,912 $ 290,041 $ 138,185 $ 4,883 $ 105,900 $ 1,276,720 Goodwill related to acquisitions — — — — — — 521,396 521,396 Currency translation and other adjustments (1,590 ) 93 — 11,186 5,735 — 1,958 17,382 Balance as of April 2, 2017 $ 343,956 $ 141,346 $ 250,912 $ 301,227 $ 143,920 $ 4,883 $ 629,254 $ 1,815,498
Schedule of Finite-Lived Intangible Assets	The following table provides information as of April 2, 2017 and December 31, 2016 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net: Gross Carrying Amount Accumulated Amortization April 2, 2017 December 31, 2016 April 2, 2017 December 31, 2016 (Dollars in thousands) Customer relationships $ 885,648 $ 622,428 $ (248,033 ) $ (239,055 ) In-process research and development 32,689 16,532 — — Intellectual property 769,892 519,962 (213,843 ) (203,390 ) Distribution rights 23,185 23,021 (15,673 ) (15,239 ) Trade names 400,406 379,724 (15,357 ) (13,974 ) Non-compete agreements 2,771 2,692 (1,231 ) (1,038 ) $ 2,114,591 $ 1,564,359 $ (494,137 ) $ (472,696 )

Borrowings (Tables)

Borrowings (Tables)	3 Months Ended
	Apr. 02, 2017
Debt Disclosure [Abstract]
Components of Long-Term Debt	The Company's borrowings at April 2, 2017 and December 31, 2016 were as follows: April 2, 2017 December 31, 2016 (Dollars in thousands) Senior Credit Facility: Revolving credit facility, at a rate of 2.46% at April 2, 2017, due 2022 $ 608,000 $ 210,000 Term loan facility, at a rate of 2.44% at April 2, 2017, due 2022 750,000 — 3.875% Convertible Senior Subordinated Notes due 2017 44,325 136,076 4.875% Senior Notes due 2026 400,000 400,000 5.25% Senior Notes due 2024 250,000 250,000 Securitization program, at a rate of 1.73% at April 2, 2017 50,000 50,000 2,102,325 1,046,076 Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017 (504 ) (2,707 ) Less: Unamortized debt issuance costs (12,929 ) (10,046 ) 2,088,892 1,033,323 Current borrowings (131,095 ) (183,071 ) Long-term borrowings $ 1,957,797 $ 850,252
Fair Value of Long-Term Debt	The following table provides the fair value of the Company’s debt as of April 2, 2017 and December 31, 2016 , categorized by the level of inputs within the fair value hierarchy used to measure fair value (see Note 10, “Fair value measurement,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 for further information regarding the fair value hierarchy): April 2, 2017 December 31, 2016 (Dollars in thousands) Level 1 $ 140,389 $ 344,765 Level 2 2,015,793 929,362 Total $ 2,156,182 $ 1,274,127

Financial instruments (Tables)

Financial instruments (Tables)	3 Months Ended
	Apr. 02, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Values of Derivative Instruments Designated as Hedging Instruments	The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of April 2, 2017 and December 31, 2016 : April 2, 2017 December 31, 2016 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 2,054 $ 667 Non-designated foreign currency forward contracts 152 490 Prepaid expenses and other current assets $ 2,206 $ 1,157 Total asset derivatives $ 2,206 $ 1,157 Liability derivatives: Designated foreign currency forward contracts $ 1,589 $ 2,139 Non-designated foreign currency forward contracts 303 118 Other current liabilities $ 1,892 $ 2,257 Total liability derivatives $ 1,892 $ 2,257
After Tax Gain (Loss) Recognized in OCI	The following table provides information as to the gains and losses attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (loss) (“OCI”) for the three months ended April 2, 2017 and March 27, 2016 : After Tax Gain (Loss) Recognized in OCI Three Months Ended April 2, 2017 March 27, 2016 (Dollars in thousands) Foreign currency forward contracts $ 1,728 $ 1,480
Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts	The following table shows the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at April 2, 2017 and December 31, 2016 : April 2, 2017 December 31, 2016 (Dollars in thousands) Allowance for doubtful accounts (1) $ 9,188 $ 8,630 Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal (2) $ 46,272 $ 51,098 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 16.4 % 19.3 % (1) The current portion of the allowance for doubtful accounts was $2.1 million and $2.0 million as of April 2, 2017 and December 31, 2016, respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at April 2, 2017 and December 31, 2016 was $3.2 million and $2.7 million , respectively In January 2017, the Company sold $16.1 million of receivables outstanding with respect to publicly funded hospitals in Italy for $16.0 million .

Fair value measurement (Tables)

Fair value measurement (Tables)	3 Months Ended
	Apr. 02, 2017
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of April 2, 2017 and December 31, 2016 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 8,048 $ 8,048 $ — $ — Derivative assets 2,206 — 2,206 — Derivative liabilities 1,892 — 1,892 — Contingent consideration liabilities (1) 7,202 — — 7,202 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 7,660 $ 7,660 $ — $ — Derivative assets 1,157 — 1,157 — Derivative liabilities 2,257 — 2,257 — Contingent consideration liabilities (1) 7,102 — — 7,102 (1) As of April 2, 2017 and December 31, 2016, $0.7 million and $0.6 million was recorded as the current portion of contingent consideration, respectively, and $6.5 million was recognized in other liabilities in the condensed consolidated balance sheet.
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes, during the three months ended April 2, 2017 , in Level 3 financial liabilities related to contingent consideration, which are described below in this Note 9 under "Valuation Techniques": Contingent consideration 2017 (Dollars in thousands) Balance - December 31, 2016 $ 7,102 Payment (79 ) Revaluations 179 Balance - April 2, 2017 $ 7,202

Shareholders' equity (Tables)

Shareholders' equity (Tables)	3 Months Ended
	Apr. 02, 2017
Equity [Abstract]
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	The following table provides a reconciliation of basic to diluted weighted average shares outstanding: Three Months Ended April 2, 2017 March 27, 2016 (Shares in thousands) Basic 44,893 41,647 Dilutive effect of share-based awards 821 519 Dilutive effect of 3.875% Convertible Notes and warrants (1) 901 6,616 Diluted 46,615 48,782 (1) The reduction in the dilutive effect of the Convertible Notes and warrants at April 2, 2017 as compared to March 27, 2016 is due to the Company’s repurchase of Convertible Notes and conversions by holders of the Convertible Notes subsequent to March 27, 2016.
Change in Accumulated Other Comprehensive Income (Loss)	The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the three months ended April 2, 2017 and March 27, 2016 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive income (loss) before reclassifications 350 (241 ) 46,982 47,091 Amounts reclassified from accumulated other comprehensive income 1,378 1,131 — 2,509 Net current-period other comprehensive income 1,728 890 46,982 49,600 Balance as of April 2, 2017 $ (696 ) $ (135,706 ) $ (252,715 ) $ (389,117 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2015 $ (2,491 ) $ (138,887 ) $ (229,746 ) $ (371,124 ) Other comprehensive (loss) before reclassifications (50 ) 182 20,476 20,608 Amounts reclassified from accumulated other comprehensive loss 1,530 1,056 — 2,586 Net current-period other comprehensive income 1,480 1,238 20,476 23,194 Balance at March 27, 2016 $ (1,011 ) $ (137,649 ) $ (209,270 ) $ (347,930 )
Reclassification of Gain/Losses into Income/Expense, Net of Tax	The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three months ended April 2, 2017 and March 27, 2016 : Three Months Ended April 2, 2017 March 27, 2016 (Dollars in thousands) Losses on foreign exchange contracts: Cost of goods sold $ 1,645 $ 1,871 Total before tax 1,645 1,871 Tax benefit (267 ) (341 ) Net of tax $ 1,378 $ 1,530 Amortization of pension and other postretirement benefit items: Actuarial losses (1) $ 1,726 $ 1,622 Prior-service costs (1) 29 14 Total before tax 1,755 1,636 Tax benefit (624 ) (580 ) Net of tax $ 1,131 $ 1,056 Total reclassifications, net of tax $ 2,509 $ 2,586 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continui33

Taxes on income from continuing operations (Tables)	3 Months Ended
	Apr. 02, 2017
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	Three Months Ended April 2, 2017 March 27, 2016 Effective income tax rate (7.1)% 4.9%

Pension and other postretirem34

Pension and other postretirement benefits (Tables)	3 Months Ended
	Apr. 02, 2017
Compensation and Retirement Disclosure [Abstract]
Net Benefit Cost of Pension and Postretirement Benefit Plans	Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits April 2, 2017 March 27, 2016 April 2, 2017 March 27, 2016 (Dollars in thousands) Service cost $ 717 $ 652 $ 74 $ 111 Interest cost 3,785 3,920 378 406 Expected return on plan assets (6,743 ) (6,198 ) — — Net amortization and deferral 1,690 1,579 65 57 Net benefits expense (income) $ (551 ) $ (47 ) $ 517 $ 574

Segment information (Tables)

Segment information (Tables)	3 Months Ended
	Apr. 02, 2017
Segment Reporting [Abstract]
Segment Results	The following tables present the Company’s segment results for the three months ended April 2, 2017 and March 27, 2016 : Three Months Ended April 2, 2017 March 27, 2016 (Dollars in thousands) Revenue Vascular North America $ 93,849 $ 81,588 Anesthesia North America 48,207 45,957 Surgical North America 45,944 38,941 EMEA 130,733 122,095 Asia 48,953 49,156 OEM 43,346 33,977 All other 76,849 53,179 Consolidated net revenues $ 487,881 $ 424,893 Three Months Ended April 2, 2017 March 27, 2016 (Dollars in thousands) Operating profit Vascular North America $ 24,816 $ 19,656 Anesthesia North America 13,527 12,177 Surgical North America 16,380 13,256 EMEA 22,240 21,043 Asia 10,798 13,008 OEM 9,121 5,189 All other (6,301 ) 5,743 Total segment operating profit (1) 90,581 90,072 Unallocated expenses (2) (29,762 ) (22,575 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 60,819 $ 67,497 (1) Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.

Condensed consolidating guara36

Condensed consolidating guarantor financial information (Tables)	3 Months Ended
	Apr. 02, 2017
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) Three Months Ended April 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 315,643 $ 276,315 $ (104,077 ) $ 487,881 Cost of goods sold — 192,001 143,896 (103,576 ) 232,321 Gross profit — 123,642 132,419 (501 ) 255,560 Selling, general and administrative expenses 20,519 94,043 48,844 563 163,969 Research and development expenses 235 11,186 6,406 — 17,827 Restructuring charges — 5,374 7,571 — 12,945 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (20,754 ) 13,039 69,598 (1,064 ) 60,819 Interest, net 47,674 (30,963 ) 846 — 17,557 Loss on extinguishment of debt 5,582 — — — 5,582 (Loss) income from continuing operations before taxes (74,010 ) 44,002 68,752 (1,064 ) 37,680 (Benefit) taxes on (loss) income from continuing operations (29,907 ) 14,485 12,229 524 (2,669 ) Equity in net income of consolidated subsidiaries 84,452 55,802 216 (140,470 ) — Income from continuing operations 40,349 85,319 56,739 (142,058 ) 40,349 Operating loss from discontinued operations (282 ) — — — (282 ) Benefit on loss from discontinued operations (103 ) — — — (103 ) Loss from discontinued operations (179 ) — — — (179 ) Net income 40,170 85,319 56,739 (142,058 ) 40,170 Other comprehensive income 49,600 49,404 53,901 (103,305 ) 49,600 Comprehensive income $ 89,770 $ 134,723 $ 110,640 $ (245,363 ) $ 89,770 Three Months Ended March 27, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 258,911 $ 261,348 $ (95,366 ) $ 424,893 Cost of goods sold — 155,541 132,963 (88,758 ) 199,746 Gross profit — 103,370 128,385 (6,608 ) 225,147 Selling, general and administrative expenses 9,329 81,477 45,059 483 136,348 Research and development expenses — 6,435 5,918 — 12,353 Restructuring charges — 4,758 5,210 — 9,968 Gain on sale of assets — — (1,019 ) — (1,019 ) (Loss) income from continuing operations before interest and taxes (9,329 ) 10,700 73,217 (7,091 ) 67,497 Interest, net 33,044 (20,318 ) 978 — 13,704 (Loss) income from continuing operations before taxes (42,373 ) 31,018 72,239 (7,091 ) 53,793 (Benefit) taxes on (loss) income from continuing operations (15,848 ) 11,677 7,864 (1,080 ) 2,613 Equity in net income of consolidated subsidiaries 77,457 57,900 168 (135,525 ) — Income from continuing operations 50,932 77,241 64,543 (141,536 ) 51,180 Operating loss from discontinued operations (382 ) — — — (382 ) (Benefit) taxes on loss from discontinued operations (139 ) — 69 — (70 ) Loss from discontinued operations (243 ) — (69 ) — (312 ) Net income 50,689 77,241 64,474 (141,536 ) 50,868 Less: Income from continuing operations attributable to noncontrolling interest — — 179 — 179 Net income attributable to common shareholders 50,689 77,241 64,295 (141,536 ) 50,689 Other comprehensive income attributable to common shareholders 23,194 18,573 22,412 (40,985 ) 23,194 Comprehensive income attributable to common shareholders $ 73,883 $ 95,814 $ 86,707 $ (182,521 ) $ 73,883
Condensed Consolidating Balance Sheets	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS April 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 153,100 $ 7,593 $ 528,436 $ — $ 689,129 Accounts receivable, net 2,215 34,464 241,897 4,296 282,872 Accounts receivable from consolidated subsidiaries 8,025 2,238,256 338,230 (2,584,511 ) — Inventories, net — 222,619 158,358 (25,688 ) 355,289 Prepaid expenses and other current assets 14,084 9,477 20,340 3,337 47,238 Prepaid taxes 11,072 — 9,527 — 20,599 Total current assets 188,496 2,512,409 1,296,788 (2,602,566 ) 1,395,127 Property, plant and equipment, net 2,517 207,818 144,899 — 355,234 Goodwill — 1,228,353 587,145 — 1,815,498 Intangibles assets, net — 1,167,974 452,480 — 1,620,454 Deferred tax assets 72,621 — 5,434 (76,092 ) 1,963 Notes receivable and other amounts due from consolidated subsidiaries 1,321,595 2,151,605 — (3,473,200 ) — Other assets 7,203,940 1,578,527 30,859 (8,769,166 ) 44,160 Total assets $ 8,789,169 $ 8,846,686 $ 2,517,605 $ (14,921,024 ) $ 5,232,436 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 81,095 $ — $ 50,000 $ — $ 131,095 Accounts payable 4,335 40,095 37,588 — 82,018 Accounts payable to consolidated subsidiaries 2,290,413 255,530 38,568 (2,584,511 ) — Accrued expenses 19,473 26,116 36,801 — 82,390 Current portion of contingent consideration — 669 — — 669 Payroll and benefit-related liabilities 16,858 15,707 33,362 — 65,927 Accrued interest 12,657 — 29 — 12,686 Income taxes payable — — 7,519 524 8,043 Other current liabilities 1,926 4,153 3,451 — 9,530 Total current liabilities 2,426,757 342,270 207,318 (2,583,987 ) 392,358 Long-term borrowings 1,957,797 — — — 1,957,797 Deferred tax liabilities — 504,454 32,292 (76,092 ) 460,654 Pension and postretirement benefit liabilities 82,623 31,223 16,380 — 130,226 Noncurrent liability for uncertain tax positions 1,432 13,731 2,776 — 17,939 Notes payable and other amounts due to consolidated subsidiaries 2,076,792 1,203,358 193,050 (3,473,200 ) — Other liabilities 24,864 15,770 13,924 — 54,558 Total liabilities 6,570,265 2,110,806 465,740 (6,133,279 ) 3,013,532 Total shareholders' equity 2,218,904 6,735,880 2,051,865 (8,787,745 ) 2,218,904 Total liabilities and shareholders' equity $ 8,789,169 $ 8,846,686 $ 2,517,605 $ (14,921,024 ) $ 5,232,436 December 31, 2016 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 14,571 $ 1,031 $ 528,187 $ — $ 543,789 Accounts receivable, net 2,551 8,768 255,815 4,859 271,993 Accounts receivable from consolidated subsidiaries 4,861 2,176,059 309,149 (2,490,069 ) — Inventories, net — 200,852 140,406 (25,087 ) 316,171 Prepaid expenses and other current assets 14,239 5,332 17,474 3,337 40,382 Prepaid taxes — — 7,766 413 8,179 Assets held for sale — — 2,879 — 2,879 Total current assets 36,222 2,392,042 1,261,676 (2,506,547 ) 1,183,393 Property, plant and equipment, net 2,566 163,847 136,486 — 302,899 Goodwill — 708,546 568,174 — 1,276,720 Intangibles assets, net — 640,999 450,664 — 1,091,663 Deferred tax assets 73,051 — 5,185 (76,524 ) 1,712 Notes receivable and other amounts due from consolidated subsidiaries 1,387,615 2,085,538 — (3,473,153 ) — Other assets 6,044,337 1,525,285 29,962 (7,564,758 ) 34,826 Total assets $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 133,071 $ — $ 50,000 $ — $ 183,071 Accounts payable 4,540 30,924 33,936 — 69,400 Accounts payable to consolidated subsidiaries 2,242,814 214,203 33,052 (2,490,069 ) — Accrued expenses 16,827 18,126 30,196 — 65,149 Current portion of contingent consideration — 587 — — 587 Payroll and benefit-related liabilities 20,610 26,672 35,397 — 82,679 Accrued interest 10,429 — 21 — 10,450 Income taxes payable 1,246 — 6,577 85 7,908 Other current liabilities 2,262 3,643 2,497 — 8,402 Total current liabilities 2,431,799 294,155 191,676 (2,489,984 ) 427,646 Long-term borrowings 850,252 — — — 850,252 Deferred tax liabilities — 316,526 31,375 (76,524 ) 271,377 Pension and postretirement benefit liabilities 85,645 31,561 15,856 — 133,062 Noncurrent liability for uncertain tax positions 1,169 13,684 2,667 — 17,520 Notes payable and other amounts due to consolidated subsidiaries 2,011,737 1,264,004 197,412 (3,473,153 ) — Other liabilities 23,848 15,695 12,472 — 52,015 Total liabilities 5,404,450 1,935,625 451,458 (6,039,661 ) 1,751,872 Convertible notes - redeemable equity component 1,824 — — — 1,824 Mezzanine equity 1,824 — — — 1,824 Total shareholders' equity 2,137,517 5,580,632 2,000,689 (7,581,321 ) 2,137,517 Total liabilities and shareholders' equity $ 7,543,791 $ 7,516,257 $ 2,452,147 $ (13,620,982 ) $ 3,891,213
Condensed Consolidating Statements of Cash Flows	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Three Months Ended April 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (86,020 ) $ 158,343 $ 80,535 $ (61,918 ) $ 90,940 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (155 ) (2,206 ) (10,533 ) — (12,894 ) Proceeds from sale of assets — — 6,332 — 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — — — (975,524 ) Net cash used in investing activities from continuing operations (975,679 ) (2,206 ) (4,201 ) — (982,086 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,194,500 — — — 1,194,500 Reduction in borrowings (138,251 ) — — — (138,251 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts (505 ) — — — (505 ) Payments for contingent consideration — (79 ) — — (79 ) Dividends paid (15,287 ) — — — (15,287 ) Intercompany transactions 179,151 (149,496 ) (29,655 ) — — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 1,200,494 (149,575 ) (91,573 ) 61,918 1,021,264 Cash flows from discontinued operations: Net cash used in operating activities (266 ) — — — (266 ) Net cash used in discontinued operations (266 ) — — — (266 ) Effect of exchange rate changes on cash and cash equivalents — — 15,488 — 15,488 Net increase in cash and cash equivalents 138,529 6,562 249 145,340 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 153,100 $ 7,593 $ 528,436 $ — $ 689,129 Three Months Ended March 27, 2016 Parent Guarantor Non-Guarantor Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (18,852 ) $ 25,624 $ 60,060 $ 66,832 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (5 ) (3,470 ) (4,347 ) (7,822 ) Proceeds from sale of assets — — 1,251 1,251 Net cash used in investing activities from continuing operations (5 ) (3,470 ) (3,096 ) (6,571 ) Cash flows from financing activities of continuing operations: Reduction in borrowings (9 ) — — (9 ) Net proceeds from share based compensation plans and the related tax impacts 3,180 — — 3,180 Payments for contingent consideration — (61 ) — (61 ) Dividends paid (14,179 ) — — (14,179 ) Intercompany transactions 32,371 (21,088 ) (11,283 ) — Net cash provided by (used in) financing activities from continuing operations 21,363 (21,149 ) (11,283 ) (11,069 ) Cash flows from discontinued operations: Net cash used in operating activities (126 ) — — (126 ) Net cash used in discontinued operations (126 ) — — (126 ) Effect of exchange rate changes on cash and cash equivalents — — 5,126 5,126 Net increase in cash and cash equivalents 2,380 1,005 50,807 54,192 Cash and cash equivalents at the beginning of the period 21,612 — 316,754 338,366 Cash and cash equivalents at the end of the period $ 23,992 $ 1,005 $ 367,561 $ 392,558

New accounting standards (Detai

New accounting standards (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net cash (used in) provided by operating activities from continuing operations	$ 90,940	$ 66,832
Net income	$ 40,170	$ 50,689
Net income (in dollars per share)	$ 0.86	$ 1.04
Accounting Standards Update 2016-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net cash (used in) provided by operating activities from continuing operations	$ 3,400
Net income	$ 3,400
Net income (in dollars per share)	$ 0.07

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) $ / shares in Units, $ in Thousands	2 Months Ended	3 Months Ended				9 Months Ended
	Apr. 02, 2017USD ($)	Apr. 02, 2017USD ($)	Sep. 25, 2016USD ($)	Jun. 26, 2016business	Mar. 27, 2016USD ($)	Sep. 25, 2016USD ($)	Feb. 17, 2017USD ($)$ / shares	Jul. 01, 2016	Jun. 30, 2016
Business Acquisition [Line Items]
Pro forma, revenue actual	$ 21,600
Pro forma, net income (loss) actual	$ 14,800
Interest expense		$ 17,726			$ 13,784
Vascular Solutions, Inc.
Business Acquisition [Line Items]
Business acquisition, share price (in dollars per share) | $ / shares							$ 56
Net assets acquired							$ 975,524
Acquisition related costs		8,900
Integration related costs		23,800
Teleflex Medical Private Limited
Business Acquisition [Line Items]
Ownership percentage									74.00%
Percentage of interests acquired								26.00%
Purchase price in excess of noncontrolling interest			$ 7,500
Medical Device and Supplies Distributors in New Zealand
Business Acquisition [Line Items]
Number of businesses acquired | business				2
2016 Acquisitions
Business Acquisition [Line Items]
Consideration transferred						$ 22,800
Bridge Loan | Vascular Solutions, Inc.
Business Acquisition [Line Items]
Interest expense		$ 2,100

Acquisitions - Assets Acquired

Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Apr. 02, 2017	Feb. 17, 2017	Dec. 31, 2016
Assets
Goodwill	$ 1,815,498		$ 1,276,720
Vascular Solutions, Inc.
Assets
Current assets		$ 64,232
Property, plant and equipment		46,886
Intangible assets		539,250
Goodwill		521,396
Other assets		728
Total assets acquired		1,172,492
Less:
Current liabilities		13,470
Deferred tax liabilities		183,498
Liabilities assumed		196,968
Net assets acquired		$ 975,524

Acquisitions - Schedule of Inta

Acquisitions - Schedule of Intangible Assets Acquired (Details) - Vascular Solutions, Inc. - USD ($) $ in Thousands	Feb. 17, 2017	Apr. 02, 2017
Business Acquisition [Line Items]
Intangible assets	$ 539,250
Intellectual property
Business Acquisition [Line Items]
Intangible assets	$ 248,200
Intellectual property | Minimum
Business Acquisition [Line Items]
Useful life	10 years
Intellectual property | Maximum
Business Acquisition [Line Items]
Useful life	20 years
In-process research and development
Business Acquisition [Line Items]
Intangible assets	$ 15,600
Trade names
Business Acquisition [Line Items]
Intangible assets	16,650
Useful life		20 years
Customer lists
Business Acquisition [Line Items]
Intangible assets	$ 258,800
Useful life		25 years

Acquisitions - Pro Forma (Detai

Acquisitions - Pro Forma (Details) - Vascular Solutions, Inc. - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Business Acquisition [Line Items]
Net revenue	$ 510,705	$ 464,124
Net income	$ 26,247	$ 36,186
Basic earnings per common share (in USD per share)	$ 0.58	$ 0.87
Diluted earnings per common share (in USD per share)	$ 0.56	$ 0.74
Basic, weighted average common shares outstanding (in shares)	44,893	41,647
Diluted, weighted average common shares outstanding (in shares)	46,615	48,782

Restructuring charges - Charges

Restructuring charges - Charges Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 12,945	$ 9,968
Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	12,750	9,852
Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	59	123
Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	59	(108)
Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	77	101
2017 Vascular Solutions Integration Program
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4,482
2017 Vascular Solutions Integration Program | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4,482
2017 Vascular Solutions Integration Program | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0
2017 Vascular Solutions Integration Program | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0
2017 Vascular Solutions Integration Program | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0
2017 EMEA Restructuring Program
Restructuring Cost and Reserve [Line Items]
Restructuring charges	7,121
2017 EMEA Restructuring Program | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	7,121
2017 EMEA Restructuring Program | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0
2017 EMEA Restructuring Program | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0
2017 EMEA Restructuring Program | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	509	10,347
2016 Footprint realignment plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	539	10,347
2016 Footprint realignment plan | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	12	0
2016 Footprint realignment plan | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(71)	0
2016 Footprint realignment plan | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	29	0
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	311
2014 Footprint realignment plan | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	303
2014 Footprint realignment plan | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0
2014 Footprint realignment plan | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0
2014 Footprint realignment plan | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	8
2017 Other Restructuring program
Restructuring Cost and Reserve [Line Items]
Restructuring charges	522
2017 Other Restructuring program | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	305
2017 Other Restructuring program | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	47
2017 Other Restructuring program | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	130
2017 Other Restructuring program | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 40
2016 Other Restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		(379)
2016 Other Restructuring programs | Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges		(495)
2016 Other Restructuring programs | Facility Closure Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		123
2016 Other Restructuring programs | Contract Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		(108)
2016 Other Restructuring programs | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 101

Restructuring charges - Additio

Restructuring charges - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 12,945	$ 9,968
Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	12,750	9,852
2017 Vascular Solutions Integration Program
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4,482
2017 Vascular Solutions Integration Program | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4,482
2017 Vascular Solutions Integration Program | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	6,000
2017 Vascular Solutions Integration Program | Minimum | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4,500
2017 Vascular Solutions Integration Program | Minimum | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	1,500
2017 Vascular Solutions Integration Program | Minimum | Retention Bonuses
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2,500
2017 Vascular Solutions Integration Program | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	7,500
2017 Vascular Solutions Integration Program | Maximum | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	5,300
2017 Vascular Solutions Integration Program | Maximum | Other Exit Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2,200
2017 Vascular Solutions Integration Program | Maximum | Retention Bonuses
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	3,000
2017 EMEA Restructuring Program
Restructuring Cost and Reserve [Line Items]
Restructuring charges	7,121
2017 EMEA Restructuring Program | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	7,121
2017 EMEA Restructuring Program | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	7,100
2017 EMEA Restructuring Program | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	8,500
2016 Other Restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring costs expected cash payment	600
Restructuring charges		(379)
Restructuring reserve	1,700
2016 Other Restructuring programs | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges		(495)
2016 Other Restructuring programs | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	1,500
2016 Other Restructuring programs | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	3,800
2016 Other Restructuring programs | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4,700
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	509	10,347
Aggregate restructuring charges incurred	13,000
Restructuring reserve	8,900
2016 Footprint realignment plan | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	539	10,347
2016 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Aggregate restructuring charges incurred	8,500
Restructuring expenses	2,100	600
2016 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	34,000
Restructuring costs expected cash payment	27,000
2016 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	44,000
Restructuring costs expected cash payment	31,000
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	311
Aggregate restructuring charges incurred	11,400
Restructuring reserve	4,800
Restructuring expenses	24,500
2014 Footprint realignment plan | Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	303
2014 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1,600	$ 2,100
2014 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	43,000
Restructuring costs expected cash payment	33,000
Expected capital expenditures	24,000
2014 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	48,000
Restructuring costs expected cash payment	38,000
Expected capital expenditures	$ 30,000

Restructuring charges - Charg44

Restructuring charges - Charges by segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 12,945	$ 9,968
Vascular North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	748	4,163
Anesthesia North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	247	1,875
Surgical North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	(19)
EMEA
Restructuring Cost and Reserve [Line Items]
Restructuring charges	7,500	3,872
Asia
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	2
OEM
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	4
All Other
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 4,450	$ 71

Inventories, net (Detail)

Inventories, net (Detail) - USD ($) $ in Thousands	Apr. 02, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 92,172	$ 65,319
Work-in-process	60,063	54,555
Finished goods	203,054	196,297
Inventories, net	$ 355,289	$ 316,171

Goodwill and other intangible46

Goodwill and other intangible assets, net - Changes in carrying amount of goodwill, by reporting segment (Details) $ in Thousands	3 Months Ended
	Apr. 02, 2017USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 1,276,720
Goodwill related to acquisitions	521,396
Currency translation and other adjustments	17,382
Goodwill, ending balance	1,815,498
Vascular North America
Goodwill [Roll Forward]
Goodwill, beginning balance	345,546
Goodwill related to acquisitions	0
Currency translation and other adjustments	(1,590)
Goodwill, ending balance	343,956
Anesthesia North America
Goodwill [Roll Forward]
Goodwill, beginning balance	141,253
Goodwill related to acquisitions	0
Currency translation and other adjustments	93
Goodwill, ending balance	141,346
Surgical North America
Goodwill [Roll Forward]
Goodwill, beginning balance	250,912
Goodwill related to acquisitions	0
Currency translation and other adjustments	0
Goodwill, ending balance	250,912
EMEA
Goodwill [Roll Forward]
Goodwill, beginning balance	290,041
Goodwill related to acquisitions	0
Currency translation and other adjustments	11,186
Goodwill, ending balance	301,227
Asia
Goodwill [Roll Forward]
Goodwill, beginning balance	138,185
Goodwill related to acquisitions	0
Currency translation and other adjustments	5,735
Goodwill, ending balance	143,920
OEM
Goodwill [Roll Forward]
Goodwill, beginning balance	4,883
Goodwill related to acquisitions	0
Currency translation and other adjustments	0
Goodwill, ending balance	4,883
All Other
Goodwill [Roll Forward]
Goodwill, beginning balance	105,900
Goodwill related to acquisitions	521,396
Currency translation and other adjustments	1,958
Goodwill, ending balance	$ 629,254

Goodwill and other intangible47

Goodwill and other intangible assets, net - Components of intangible assets (Details) - USD ($) $ in Thousands	Apr. 02, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,114,591	$ 1,564,359
Accumulated amortization	(494,137)	(472,696)
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	32,689	16,532
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	885,648	622,428
Accumulated amortization	(248,033)	(239,055)
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	769,892	519,962
Accumulated amortization	(213,843)	(203,390)
Distribution rights
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	23,185	23,021
Accumulated amortization	(15,673)	(15,239)
Trade names
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	400,406	379,724
Accumulated amortization	(15,357)	(13,974)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	2,771	2,692
Accumulated amortization	$ (1,231)	$ (1,038)

Borrowings - Components of long

Borrowings - Components of long-term debt (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Total borrowings	$ 2,102,325	$ 1,046,076
Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017	(504)	(2,707)
Less: Unamortized debt issuance costs	(12,929)	(10,046)
Total long-term debt	2,088,892	1,033,323
Current borrowings	(131,095)	(183,071)
Long-term borrowings	1,957,797	850,252
Revolving Credit Facility
Debt Instrument [Line Items]
Senior Credit Facility:	$ 608,000	210,000
Line of credit facility interest rate	2.46%
Term Loan
Debt Instrument [Line Items]
Senior Credit Facility:	$ 750,000	0
Line of credit facility interest rate	2.44%
Senior Notes | 3.875% Convertible Senior Subordinated Notes due 2017
Debt Instrument [Line Items]
3.875% Convertible Senior Subordinated Notes due 2017	$ 44,325	136,076
Debt instrument, stated interest rate	3.875%
Senior Notes | 4.875% Senior Notes due 2026
Debt Instrument [Line Items]
Senior Notes	$ 400,000	400,000
Debt instrument, stated interest rate	4.875%
Senior Notes | 5.25% Senior Notes due 2024
Debt Instrument [Line Items]
Senior Notes	$ 250,000	250,000
Debt instrument, stated interest rate	5.25%
Securitization program, at a rate of 1.73% at April 2, 2017
Debt Instrument [Line Items]
Securitization program, at a rate of 1.73% at April 2, 2017	$ 50,000	$ 50,000
Debt instrument, stated interest rate	1.73%

Borrowings - Amended and restat

Borrowings - Amended and restated credit facility (Details)	Jan. 20, 2017USD ($)	Apr. 02, 2017USD ($)	Mar. 27, 2016USD ($)
Line of Credit Facility [Line Items]
Loss on extinguishment of debt		$ 5,582,000	$ 0
2017 Credit Agreement
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	2.00%
Maximum leverage ratio	4.50
Maximum secured leverage ratio	3.50
Minimum interest coverage ratio	3.50
Line of credit, debt issuance cost		12,000,000
2017 Credit Agreement | Revolving Credit Facility
Line of Credit Facility [Line Items]
Debt instrument term	5 years
Maximum borrowing capacity	$ 1,000,000,000
2017 Credit Agreement | Term Loan
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 750,000,000
2013 Credit Agreement
Line of Credit Facility [Line Items]
Loss on extinguishment of debt		$ 400,000
London Interbank Offered Rate (LIBOR) | Minimum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.25%
London Interbank Offered Rate (LIBOR) | Maximum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	2.50%
Federal Funds Effective Swap Rate | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
Adjusted LIBOR | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Adjusted LIBOR | Minimum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.25%
Adjusted LIBOR | Maximum | 2017 Credit Agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.50%

Borrowings - 3.875% Convertible

Borrowings - 3.875% Convertible Senior Subordinated Notes (Details) - USD ($) shares in Thousands	Jan. 05, 2017	Apr. 02, 2017	Mar. 27, 2016
Short-term Debt [Line Items]
Repayments of debt		$ 138,251,000	$ 9,000
Conversion of convertible notes, shares issued upon conversion		400	3,000
Loss on extinguishment of debt		$ 5,582,000	$ 0
Shares received from dealer counterparties		120
3.875% Convertible Senior Subordinated Notes due 2017 | Senior Notes
Short-term Debt [Line Items]
Extinguishment of debt, amount	$ 91,700,000
Principal amount of convertible debt	1,000
Repayments of debt	93,200,000
Repayments of debt, accrued interest	$ 1,500,000
Conversion of convertible notes, shares issued upon conversion	930
Loss on extinguishment of debt		$ 5,200,000

Borrowings - Fair value of long

Borrowings - Fair value of long term debt (Details) - USD ($) $ in Thousands	Apr. 02, 2017	Dec. 31, 2016
Fair Value Measurements [Line Items]
Fair value of debt	$ 2,156,182	$ 1,274,127
Level 1
Fair Value Measurements [Line Items]
Fair value of debt	140,389	344,765
Level 2
Fair Value Measurements [Line Items]
Fair value of debt	$ 2,015,793	$ 929,362

Financial instruments - Additio

Financial instruments - Additional Information (Detail) - USD ($)	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016	Dec. 31, 2016
Derivatives Fair Value [Line Items]
Net revenues	$ 487,881,000	$ 424,893,000
Spain, Italy, Portugal, and Greece
Derivatives Fair Value [Line Items]
Net revenues	31,500,000	30,900,000
Cash flow hedging
Derivatives Fair Value [Line Items]
Ineffectiveness related to derivatives	0
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	124,400,000		$ 101,800,000
Foreign exchange contract | Not Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Loss related to currency forward contracts	800,000	$ 300,000
Total notional amount for all open foreign currency forward contracts	$ 79,300,000		$ 73,400,000

Financial instruments - Fair va

Financial instruments - Fair values of derivative instruments designated as hedging instruments (Details) - USD ($) $ in Thousands	Apr. 02, 2017	Dec. 31, 2016
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 2,206	$ 1,157
Total liability derivatives	1,892	2,257
Foreign exchange contract | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	2,206	1,157
Foreign exchange contract | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	1,892	2,257
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	2,054	667
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	1,589	2,139
Foreign exchange contract | Not Designated as Hedging Instrument | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	152	490
Foreign exchange contract | Not Designated as Hedging Instrument | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 303	$ 118

Financial instruments - After t

Financial instruments - After tax gains and losses reclassified from accumulated other comprehensive income into income (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Foreign exchange contract | Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
After Tax Gain (Loss) Recognized in OCI	$ 1,728	$ 1,480

Financial instruments - Aggrega

Financial instruments - Aggregate accounts receivable, net of allowance for doubtful accounts (Details) - USD ($) $ in Thousands	1 Months Ended
	Jan. 31, 2017	Apr. 02, 2017	Dec. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts receivable		$ 9,188	$ 8,630
Allowance for doubtful accounts		2,100	2,000
Spain, Italy, Portugal, and Greece
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal		$ 46,272	$ 51,098
Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal		16.40%	19.30%
Long-term portion of accounts receivable, net		$ 3,200	$ 2,700
Italy
Accounts, Notes, Loans and Financing Receivable [Line Items]
Financing receivable, significant sales	$ 16,100
Proceeds from sale of receivables	$ 16,000

Fair value measurement - Financ

Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Details) - USD ($) $ in Thousands	Apr. 02, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 8,048	$ 7,660
Derivative assets	2,206	1,157
Derivative liabilities	1,892	2,257
Contingent consideration liabilities	7,202	7,102
Current portion of contingent consideration	669	587
Fair value measurement with unobservable inputs reconciliations other liabilities	6,500	6,500
Quoted prices in active markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	8,048	7,660
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	0	0
Significant other observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	2,206	1,157
Derivative liabilities	1,892	2,257
Contingent consideration liabilities	0	0
Significant unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	$ 7,202	$ 7,102

Fair value measurement - Reconc

Fair value measurement - Reconciliation of changes in financial liabilities measured on recurring basis (Details) $ in Thousands	3 Months Ended
	Apr. 02, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 7,102
Payment	(79)
Revaluations	179
Ending balance	$ 7,202

Shareholders' equity - Addition

Shareholders' equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016	Dec. 31, 2016
Shareholders Equity [Line Items]
Investment warrants, exercise price (in dollars per share)	$ 74.65
Conversion of convertible notes, shares issued upon conversion	0.4	3
Convertible notes - redeemable equity component	$ 0		$ 1,824
Equity Option
Shareholders Equity [Line Items]
Weighted average antidilutive shares which were not included in the calculation of earnings per share	0.5	5.2
Convertible Note
Shareholders Equity [Line Items]
Weighted average antidilutive shares which were not included in the calculation of earnings per share	0.5	3.6

Shareholders' equity - Reconcil

Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Details) - shares shares in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Debt Instrument [Line Items]
Basic (in shares)	44,893	41,647
Dilutive effect of share-based awards (in shares)	821	519
Dilutive effect of 3.875% Convertible Notes and warrants (in shares)	901	6,616
Diluted (in shares)	46,615	48,782
Senior Notes | 3.875% Convertible Senior Subordinated Notes due 2017
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.875%

Shareholders' equity - Change i

Shareholders' equity - Change in accumulated other comprehensive income, net of tax (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$ 2,137,517
Other comprehensive income (loss) before reclassifications	47,091	$ 20,608
Amounts reclassified from accumulated other comprehensive income	2,509	2,586
Net current-period other comprehensive income	49,600	23,194
Ending Balance	2,218,904
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(2,424)	(2,491)
Other comprehensive income (loss) before reclassifications	350	(50)
Amounts reclassified from accumulated other comprehensive income	1,378	1,530
Net current-period other comprehensive income	1,728	1,480
Ending Balance	(696)	(1,011)
Pension and Other Postretirement Benefit Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(136,596)	(138,887)
Other comprehensive income (loss) before reclassifications	(241)	182
Amounts reclassified from accumulated other comprehensive income	1,131	1,056
Net current-period other comprehensive income	890	1,238
Ending Balance	(135,706)	(137,649)
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(299,697)	(229,746)
Other comprehensive income (loss) before reclassifications	46,982	20,476
Amounts reclassified from accumulated other comprehensive income	0	0
Net current-period other comprehensive income	46,982	20,476
Ending Balance	(252,715)	(209,270)
Accumulated Other Comprehensive (Loss) Income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(438,717)	(371,124)
Ending Balance	$ (389,117)	$ (347,930)

Shareholders' equity - Accumula

Shareholders' equity - Accumulated other comprehensive income into income expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$ (232,321)	$ (199,746)
Total reclassifications, net of tax	2,509	2,586
Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	1,645	1,871
Total before tax	1,645	1,871
Tax benefit	(267)	(341)
Total reclassifications, net of tax	1,378	1,530
Actuarial losses
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,726	1,622
Prior-service costs
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	29	14
Pension and Other Postretirement Benefits Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,755	1,636
Tax benefit	(624)	(580)
Total reclassifications, net of tax	$ 1,131	$ 1,056

Taxes on income from continui62

Taxes on income from continuing operations (Details)	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Income Tax Disclosure [Abstract]
Effective income tax rate	(7.10%)	4.90%

Pension and other postretirem63

Pension and other postretirement benefits (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Pension
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 717	$ 652
Interest cost	3,785	3,920
Expected return on plan assets	(6,743)	(6,198)
Net amortization and deferral	1,690	1,579
Net benefits expense (income)	(551)	(47)
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	74	111
Interest cost	378	406
Expected return on plan assets	0	0
Net amortization and deferral	65	57
Net benefits expense (income)	$ 517	$ 574

Commitments and contingent li64

Commitments and contingent liabilities (Detail) ¥ in Millions, $ in Millions	Dec. 05, 2014USD ($)	Apr. 02, 2017USD ($)	Apr. 02, 2017CNY (¥)
Loss Contingencies [Line Items]
Estimated litigation liability		$ 2.4
Minimum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out		15 years	15 years
Maximum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out		20 years	20 years
Accrued Liabilities
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies		$ 1.1
Other Liability
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies		5.6
Discontinued Operations
Loss Contingencies [Line Items]
Estimated litigation liability		1.7
Distributor vs Teleflex Medical Trading Company, Ltd.
Loss Contingencies [Line Items]
Damages sought		10.1	¥ 69.3
Distributor vs Teleflex Medical Trading Company, Ltd. Repurchase of Inventory
Loss Contingencies [Line Items]
Damages sought		9.1	63
Teleflex Medical Trading Company, Ltd. vs Distributor - Outstanding Receivables
Loss Contingencies [Line Items]
Damages sought		8.9	¥ 61.2
Compensatory Damages | Judicial Ruling | Parish of Calcasieu
Loss Contingencies [Line Items]
Damages awarded	$ 0.1
Punitive Damages | Judicial Ruling | Parish of Calcasieu
Loss Contingencies [Line Items]
Damages awarded	$ 23
Unfavorable Regulatory Action | Judicial Ruling | Parish of Calcasieu | Maximum
Loss Contingencies [Line Items]
Estimate of possible loss		$ 10

Segment information (Details)

Segment information (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 487,881	$ 424,893
Operating profit	60,819	67,497
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	90,581	90,072
Unallocated expenses
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	(29,762)	(22,575)
Vascular North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	93,849	81,588
Vascular North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	24,816	19,656
Anesthesia North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	48,207	45,957
Anesthesia North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	13,527	12,177
Surgical North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	45,944	38,941
Surgical North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	16,380	13,256
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	130,733	122,095
EMEA | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	22,240	21,043
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	48,953	49,156
Asia | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	10,798	13,008
OEM
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	43,346	33,977
OEM | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	9,121	5,189
All other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	76,849	53,179
All other | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	$ (6,301)	$ 5,743

Condensed consolidating guara66

Condensed consolidating guarantor financial information - Additional Information (Detail) - Senior Notes	Apr. 02, 2017
5.25% Senior Notes due 2024
Condensed Financial Statements Captions [Line Items]
Debt instrument, stated interest rate	5.25%
4.875% Senior Notes due 2026
Condensed Financial Statements Captions [Line Items]
Debt instrument, stated interest rate	4.875%

Condensed consolidating guara67

Condensed consolidating guarantor financial information - Income and Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Condensed Income Statements, Captions [Line Items]
Net revenues	$ 487,881	$ 424,893
Cost of goods sold	232,321	199,746
Gross profit	255,560	225,147
Selling, general and administrative expenses	163,969	136,348
Research and development expenses	17,827	12,353
Restructuring charges	12,945	9,968
Gain on sale of assets	0	(1,019)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	60,819	67,497
Interest, net	17,557	13,704
Loss on extinguishment of debt	5,582	0
Income from continuing operations before taxes	37,680	53,793
(Benefit) taxes on (loss) income from continuing operations	(2,669)	2,613
Equity in net income of consolidated subsidiaries	0	0
Income from continuing operations	40,349	51,180
Operating income from discontinued operations	(282)	(382)
Tax on income from discontinued operations	(103)	(70)
Loss from discontinued operations	(179)	(312)
Net income	40,170	50,868
Less: Income from continuing operations attributable to noncontrolling interest	0	179
Net income attributable to common shareholders	40,170	50,689
Other comprehensive income (loss) attributable to common shareholders	49,600	23,194
Comprehensive income attributable to common shareholders	89,770	73,883
Reportable Legal Entities | Parent Company
Condensed Income Statements, Captions [Line Items]
Net revenues	0	0
Cost of goods sold	0	0
Gross profit	0	0
Selling, general and administrative expenses	20,519	9,329
Research and development expenses	235	0
Restructuring charges	0	0
Gain on sale of assets		0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	(20,754)	(9,329)
Interest, net	47,674	33,044
Loss on extinguishment of debt	5,582
Income from continuing operations before taxes	(74,010)	(42,373)
(Benefit) taxes on (loss) income from continuing operations	(29,907)	(15,848)
Equity in net income of consolidated subsidiaries	84,452	77,457
Income from continuing operations	40,349	50,932
Operating income from discontinued operations	(282)	(382)
Tax on income from discontinued operations	(103)	(139)
Loss from discontinued operations	(179)	(243)
Net income	40,170	50,689
Less: Income from continuing operations attributable to noncontrolling interest		0
Net income attributable to common shareholders		50,689
Other comprehensive income (loss) attributable to common shareholders	49,600	23,194
Comprehensive income attributable to common shareholders	89,770	73,883
Reportable Legal Entities | Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	315,643	258,911
Cost of goods sold	192,001	155,541
Gross profit	123,642	103,370
Selling, general and administrative expenses	94,043	81,477
Research and development expenses	11,186	6,435
Restructuring charges	5,374	4,758
Gain on sale of assets		0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	13,039	10,700
Interest, net	(30,963)	(20,318)
Loss on extinguishment of debt	0
Income from continuing operations before taxes	44,002	31,018
(Benefit) taxes on (loss) income from continuing operations	14,485	11,677
Equity in net income of consolidated subsidiaries	55,802	57,900
Income from continuing operations	85,319	77,241
Operating income from discontinued operations	0	0
Tax on income from discontinued operations	0	0
Loss from discontinued operations	0	0
Net income	85,319	77,241
Less: Income from continuing operations attributable to noncontrolling interest		0
Net income attributable to common shareholders		77,241
Other comprehensive income (loss) attributable to common shareholders	49,404	18,573
Comprehensive income attributable to common shareholders	134,723	95,814
Reportable Legal Entities | Non-Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	276,315	261,348
Cost of goods sold	143,896	132,963
Gross profit	132,419	128,385
Selling, general and administrative expenses	48,844	45,059
Research and development expenses	6,406	5,918
Restructuring charges	7,571	5,210
Gain on sale of assets		(1,019)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	69,598	73,217
Interest, net	846	978
Loss on extinguishment of debt	0
Income from continuing operations before taxes	68,752	72,239
(Benefit) taxes on (loss) income from continuing operations	12,229	7,864
Equity in net income of consolidated subsidiaries	216	168
Income from continuing operations	56,739	64,543
Operating income from discontinued operations	0	0
Tax on income from discontinued operations	0	69
Loss from discontinued operations	0	(69)
Net income	56,739	64,474
Less: Income from continuing operations attributable to noncontrolling interest		179
Net income attributable to common shareholders		64,295
Other comprehensive income (loss) attributable to common shareholders	53,901	22,412
Comprehensive income attributable to common shareholders	110,640	86,707
Eliminations
Condensed Income Statements, Captions [Line Items]
Net revenues	(104,077)	(95,366)
Cost of goods sold	(103,576)	(88,758)
Gross profit	(501)	(6,608)
Selling, general and administrative expenses	563	483
Research and development expenses	0	0
Restructuring charges	0	0
Gain on sale of assets		0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	(1,064)	(7,091)
Interest, net	0	0
Loss on extinguishment of debt	0
Income from continuing operations before taxes	(1,064)	(7,091)
(Benefit) taxes on (loss) income from continuing operations	524	(1,080)
Equity in net income of consolidated subsidiaries	(140,470)	(135,525)
Income from continuing operations	(142,058)	(141,536)
Operating income from discontinued operations	0	0
Tax on income from discontinued operations	0	0
Loss from discontinued operations	0	0
Net income	(142,058)	(141,536)
Less: Income from continuing operations attributable to noncontrolling interest		0
Net income attributable to common shareholders		(141,536)
Other comprehensive income (loss) attributable to common shareholders	(103,305)	(40,985)
Comprehensive income attributable to common shareholders	$ (245,363)	$ (182,521)

Condensed consolidating guara68

Condensed consolidating guarantor financial information - Balance Sheets (Details) - USD ($) $ in Thousands	Apr. 02, 2017	Dec. 31, 2016	Mar. 27, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 689,129	$ 543,789	$ 392,558	$ 338,366
Accounts receivable, net	282,872	271,993
Accounts receivable from consolidated subsidiaries	0	0
Inventories, net	355,289	316,171
Prepaid expenses and other current assets	47,238	40,382
Prepaid taxes	20,599	8,179
Assets held for sale	0	2,879
Total current assets	1,395,127	1,183,393
Property, plant and equipment, net	355,234	302,899
Goodwill	1,815,498	1,276,720
Intangible assets, net	1,620,454	1,091,663
Deferred tax assets	1,963	1,712
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	44,160	34,826
Total assets	5,232,436	3,891,213
Current liabilities
Current borrowings	131,095	183,071
Accounts payable	82,018	69,400
Accounts payable to consolidated subsidiaries	0	0
Accrued expenses	82,390	65,149
Current portion of contingent consideration	669	587
Payroll and benefit-related liabilities	65,927	82,679
Accrued interest	12,686	10,450
Income taxes payable	8,043	7,908
Other current liabilities	9,530	8,402
Total current liabilities	392,358	427,646
Long-term borrowings	1,957,797	850,252
Deferred tax liabilities	460,654	271,377
Pension and postretirement benefit liabilities	130,226	133,062
Noncurrent liability for uncertain tax positions	17,939	17,520
Notes payable and other amounts due to consolidated subsidiaries	0	0
Other liabilities	54,558	52,015
Total liabilities	3,013,532	1,751,872
Convertible notes - redeemable equity component	0	1,824
Mezzanine equity	0	1,824
Total shareholders' equity	2,218,904	2,137,517
Total liabilities and shareholders' equity	5,232,436	3,891,213
Reportable Legal Entities | Parent Company
Current assets
Cash and cash equivalents	153,100	14,571	23,992	21,612
Accounts receivable, net	2,215	2,551
Accounts receivable from consolidated subsidiaries	8,025	4,861
Inventories, net	0	0
Prepaid expenses and other current assets	14,084	14,239
Prepaid taxes	11,072	0
Assets held for sale		0
Total current assets	188,496	36,222
Property, plant and equipment, net	2,517	2,566
Goodwill	0	0
Intangible assets, net	0	0
Deferred tax assets	72,621	73,051
Notes receivable and other amounts due from consolidated subsidiaries	1,321,595	1,387,615
Other assets	7,203,940	6,044,337
Total assets	8,789,169	7,543,791
Current liabilities
Current borrowings	81,095	133,071
Accounts payable	4,335	4,540
Accounts payable to consolidated subsidiaries	2,290,413	2,242,814
Accrued expenses	19,473	16,827
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	16,858	20,610
Accrued interest	12,657	10,429
Income taxes payable	0	1,246
Other current liabilities	1,926	2,262
Total current liabilities	2,426,757	2,431,799
Long-term borrowings	1,957,797	850,252
Deferred tax liabilities	0	0
Pension and postretirement benefit liabilities	82,623	85,645
Noncurrent liability for uncertain tax positions	1,432	1,169
Notes payable and other amounts due to consolidated subsidiaries	2,076,792	2,011,737
Other liabilities	24,864	23,848
Total liabilities	6,570,265	5,404,450
Convertible notes - redeemable equity component		1,824
Mezzanine equity		1,824
Total shareholders' equity	2,218,904	2,137,517
Total liabilities and shareholders' equity	8,789,169	7,543,791
Reportable Legal Entities | Guarantor Subsidiaries
Current assets
Cash and cash equivalents	7,593	1,031	1,005	0
Accounts receivable, net	34,464	8,768
Accounts receivable from consolidated subsidiaries	2,238,256	2,176,059
Inventories, net	222,619	200,852
Prepaid expenses and other current assets	9,477	5,332
Prepaid taxes	0	0
Assets held for sale		0
Total current assets	2,512,409	2,392,042
Property, plant and equipment, net	207,818	163,847
Goodwill	1,228,353	708,546
Intangible assets, net	1,167,974	640,999
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	2,151,605	2,085,538
Other assets	1,578,527	1,525,285
Total assets	8,846,686	7,516,257
Current liabilities
Current borrowings	0	0
Accounts payable	40,095	30,924
Accounts payable to consolidated subsidiaries	255,530	214,203
Accrued expenses	26,116	18,126
Current portion of contingent consideration	669	587
Payroll and benefit-related liabilities	15,707	26,672
Accrued interest	0	0
Income taxes payable	0	0
Other current liabilities	4,153	3,643
Total current liabilities	342,270	294,155
Long-term borrowings	0	0
Deferred tax liabilities	504,454	316,526
Pension and postretirement benefit liabilities	31,223	31,561
Noncurrent liability for uncertain tax positions	13,731	13,684
Notes payable and other amounts due to consolidated subsidiaries	1,203,358	1,264,004
Other liabilities	15,770	15,695
Total liabilities	2,110,806	1,935,625
Convertible notes - redeemable equity component		0
Mezzanine equity		0
Total shareholders' equity	6,735,880	5,580,632
Total liabilities and shareholders' equity	8,846,686	7,516,257
Reportable Legal Entities | Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	528,436	528,187	$ 367,561	$ 316,754
Accounts receivable, net	241,897	255,815
Accounts receivable from consolidated subsidiaries	338,230	309,149
Inventories, net	158,358	140,406
Prepaid expenses and other current assets	20,340	17,474
Prepaid taxes	9,527	7,766
Assets held for sale		2,879
Total current assets	1,296,788	1,261,676
Property, plant and equipment, net	144,899	136,486
Goodwill	587,145	568,174
Intangible assets, net	452,480	450,664
Deferred tax assets	5,434	5,185
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	30,859	29,962
Total assets	2,517,605	2,452,147
Current liabilities
Current borrowings	50,000	50,000
Accounts payable	37,588	33,936
Accounts payable to consolidated subsidiaries	38,568	33,052
Accrued expenses	36,801	30,196
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	33,362	35,397
Accrued interest	29	21
Income taxes payable	7,519	6,577
Other current liabilities	3,451	2,497
Total current liabilities	207,318	191,676
Long-term borrowings	0	0
Deferred tax liabilities	32,292	31,375
Pension and postretirement benefit liabilities	16,380	15,856
Noncurrent liability for uncertain tax positions	2,776	2,667
Notes payable and other amounts due to consolidated subsidiaries	193,050	197,412
Other liabilities	13,924	12,472
Total liabilities	465,740	451,458
Convertible notes - redeemable equity component		0
Mezzanine equity		0
Total shareholders' equity	2,051,865	2,000,689
Total liabilities and shareholders' equity	2,517,605	2,452,147
Eliminations
Current assets
Cash and cash equivalents	0	0
Accounts receivable, net	4,296	4,859
Accounts receivable from consolidated subsidiaries	(2,584,511)	(2,490,069)
Inventories, net	(25,688)	(25,087)
Prepaid expenses and other current assets	3,337	3,337
Prepaid taxes	0	413
Assets held for sale		0
Total current assets	(2,602,566)	(2,506,547)
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Deferred tax assets	(76,092)	(76,524)
Notes receivable and other amounts due from consolidated subsidiaries	(3,473,200)	(3,473,153)
Other assets	(8,769,166)	(7,564,758)
Total assets	(14,921,024)	(13,620,982)
Current liabilities
Current borrowings	0	0
Accounts payable	0	0
Accounts payable to consolidated subsidiaries	(2,584,511)	(2,490,069)
Accrued expenses	0	0
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	0	0
Accrued interest	0	0
Income taxes payable	524	85
Other current liabilities	0	0
Total current liabilities	(2,583,987)	(2,489,984)
Long-term borrowings	0	0
Deferred tax liabilities	(76,092)	(76,524)
Pension and postretirement benefit liabilities	0	0
Noncurrent liability for uncertain tax positions	0	0
Notes payable and other amounts due to consolidated subsidiaries	(3,473,200)	(3,473,153)
Other liabilities	0	0
Total liabilities	(6,133,279)	(6,039,661)
Convertible notes - redeemable equity component		0
Mezzanine equity		0
Total shareholders' equity	(8,787,745)	(7,581,321)
Total liabilities and shareholders' equity	$ (14,921,024)	$ (13,620,982)

Condensed consolidating guara69

Condensed consolidating guarantor financial information - Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2017	Mar. 27, 2016
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	$ 90,940	$ 66,832
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(12,894)	(7,822)
Proceeds from sale of assets	6,332	1,251
Payments for businesses and intangibles acquired, net of cash acquired	(975,524)	0
Net cash used in investing activities from continuing operations	(982,086)	(6,571)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	1,194,500	0
Reduction in borrowings	(138,251)	(9)
Debt extinguishment, issuance and amendment fees	(19,114)	0
Net proceeds from share based compensation plans and the related tax impacts	(505)	3,180
Payments for contingent consideration	(79)	(61)
Dividends paid	(15,287)	(14,179)
Intercompany transactions	0	0
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	1,021,264	(11,069)
Cash flows from discontinued operations:
Net cash used in operating activities	(266)	(126)
Net cash used in discontinued operations	(266)	(126)
Effect of exchange rate changes on cash and cash equivalents	15,488	5,126
Net increase in cash and cash equivalents	145,340	54,192
Cash and cash equivalents at the beginning of the period	543,789	338,366
Cash and cash equivalents at the end of the period	689,129	392,558
Reportable Legal Entities | Parent Company
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(86,020)	(18,852)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(155)	(5)
Proceeds from sale of assets	0	0
Payments for businesses and intangibles acquired, net of cash acquired	(975,524)
Net cash used in investing activities from continuing operations	(975,679)	(5)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	1,194,500
Reduction in borrowings	(138,251)	(9)
Debt extinguishment, issuance and amendment fees	(19,114)
Net proceeds from share based compensation plans and the related tax impacts	(505)	3,180
Payments for contingent consideration	0	0
Dividends paid	(15,287)	(14,179)
Intercompany transactions	179,151	32,371
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	1,200,494	21,363
Cash flows from discontinued operations:
Net cash used in operating activities	(266)	(126)
Net cash used in discontinued operations	(266)	(126)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	138,529	2,380
Cash and cash equivalents at the beginning of the period	14,571	21,612
Cash and cash equivalents at the end of the period	153,100	23,992
Reportable Legal Entities | Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	158,343	25,624
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(2,206)	(3,470)
Proceeds from sale of assets	0	0
Payments for businesses and intangibles acquired, net of cash acquired	0
Net cash used in investing activities from continuing operations	(2,206)	(3,470)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	(79)	(61)
Dividends paid	0	0
Intercompany transactions	(149,496)	(21,088)
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	(149,575)	(21,149)
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	6,562	1,005
Cash and cash equivalents at the beginning of the period	1,031	0
Cash and cash equivalents at the end of the period	7,593	1,005
Reportable Legal Entities | Non-Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	80,535	60,060
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(10,533)	(4,347)
Proceeds from sale of assets	6,332	1,251
Payments for businesses and intangibles acquired, net of cash acquired	0
Net cash used in investing activities from continuing operations	(4,201)	(3,096)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0	0
Dividends paid	0	0
Intercompany transactions	(29,655)	(11,283)
Intercompany dividends paid	(61,918)
Net cash provided by (used in) financing activities from continuing operations	(91,573)	(11,283)
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	15,488	5,126
Net increase in cash and cash equivalents	249	50,807
Cash and cash equivalents at the beginning of the period	528,187	316,754
Cash and cash equivalents at the end of the period	528,436	$ 367,561
Eliminations
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(61,918)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	0
Proceeds from sale of assets	0
Payments for businesses and intangibles acquired, net of cash acquired	0
Net cash used in investing activities from continuing operations	0
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0
Reduction in borrowings	0
Debt extinguishment, issuance and amendment fees	0
Net proceeds from share based compensation plans and the related tax impacts	0
Payments for contingent consideration	0
Dividends paid	0
Intercompany transactions	0
Intercompany dividends paid	61,918
Net cash provided by (used in) financing activities from continuing operations	61,918
Cash flows from discontinued operations:
Net cash used in operating activities	0
Net cash used in discontinued operations	0
Effect of exchange rate changes on cash and cash equivalents	0
Net increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the period	0
Cash and cash equivalents at the end of the period	$ 0